ASCOT Statistical Analysis Report

James Totterdell   Rob Mahar

2023-02-01

Table of contents

List of Figures

7

11

List of Tables

15

1 Introduction

1.1 Purpose

The trial steering committee (TSC) closed randomisation to the anticoagulation domain on 2022-04-08. The blinded statistical analysis working group prepared a statistical analysis plan (SAP) for reporting the results of the anticoagulation domain. The unblinded team of statisticians undertook the analyses using the relevant records as extracted from the database on 2022-06-06.

Subsequently, the TSC closed randomisation to the antiviral domain on 2022-08-11. The blinded statistical analysis group prepared a SAP for reporting the results of the antiviral domain. Given all study domains have closed, the unblinded team of statisticians undertook final analyses using the relevant records as extracted from the database on 2022-10-26.

This report summarises the data and results of the analyses for the ASCOT trial. The report focuses on the antiviral domain but also reports on the anticoagulation domain for completeness sake.

1.2 Interventions

There were two mutually exclusive interventions in the antiviral domain. They were:

- no specific antiviral (standard of care, control)
- Nafamostat

There were four mutually exclusive interventions in the anticoagulation domain. They were:

- low-dose thromboprophylaxis (control)
- intermediate-dose thromboprophylaxis

- low-dose thromboprophylaxis with aspirin
- therapeutic-dose thromboprophylaxis

For full details of the interventions, refer to the domain specific appendices to the protocol.

1.3 Outcomes

For details on the primary and secondary outcomes, refer to the core protocol. For details on the domain specific outcomes refer to the anticoagulation domain-specific appendix.

1.4 Modelling

1.4.1 General Considerations

All binary outcomes were analysed using a logistic regression model, ordinal outcomes by a cumulative logistic model with proportional odds, and the time to recovery outcome by a discrete-time competing-risk (death) time-to-event model (multinomial logistic regression). Weakly informative priors were specified for all models.

The (pre-specified) primary model for all outcomes included fixed terms for:

- anticoagulation intervention
- antiviral intervention
- intervention ineligibility (eligible for aspirin, ineligible for aspirin)
- age group (< 60, ≥ 60 years of age)
- sex (male, female)
- oxygen requirement (did not require supplemental oxygen, did require supplemental oxygen)
- region of enrolment (India, Australia/New Zealand, Nepal)

Hierarchical terms were also included for:

- site of enrolment (nested within region)
- epoch of enrolment (4-week groupings)

Outcomes are coded such that an odds ratio less than 1 implies a decrease in the outcome, for example, lower odds of 28 day mortality, fewer days alive and free of hospital, etc. Therefore, depending on the outcome, an odds ratio less than 1 may imply benefit or harm, but this will be made clear for each outcome.

In general, the reference group (to which the model intercept(s) or baseline hazard applies) was taken to be a patient who was:

- randomised to the anticoagulation domain (equal weighting across all interventions)
- *not* randomised to the antiviral domain
- eligible for aspirin intervention
- less than 60 years of age
- was male
- did not require supplemental oxygen
- enrolled in India during the most recent epoch

based on the most prevalent level of each covariate.

Bayesian models were computed using Stan via `cmdstanr` (0.5.2 and cmdstan version 2.30.1) in R (4.2.2). For each model, 8 chains were used with a warm-up of 1000 iterations and sampling for 2500 iterations per chain resulting in 20,000 posterior draws per model. Standard diagnostics were assessed for each model (divergent transitions, trace plots, R-hat). If an issue was identified (e.g. divergent transitions) then the default sampling parameters may have been adjusted (e.g. increasing target acceptance rate or increasing maximum tree depth). If any convergence issues resulted for the pre-specified models, then they are reported along with the model results. If the model was amended in any way to satisfy convergence criteria (e.g. aggregation of groups, removal of model terms) then this is reported in the relevant section. Sampling was run using a different (randomly selected) random seed for each model, and these were recorded for replication.

Due to the small number of enrolments at New Zealand sites, in models where country of enrolment were included as a term, Australia and New Zealand were combined into one region. The hierarchical site effects for centres in Australia and New Zealand were nested within this joint region rather than each country individually. For models where site was included as a random effect, sites with less than 5 participants were aggregated within region into an "other sites" grouping. Similarly, for models where epoch was included, epochs with less than 10 participants were aggregated with the adjacent epoch.

Missing outcome data were not imputed for any of the models (with the exception of the deterministic imputation used in the best-case/worst-case sensitivity analyses). The only baseline covariate of interest which had missing values was oxygen requirement. For the primary analyses, participants with missing information for oxygen requirement (25 participants in full analysis set) were assumed to have *not* required supplemental oxygen.

1.4.2 Further Details

For all models, the primary linear predictor was the same. For a participant i with outcome y_i, their region of enrolment is denoted by $r(i) \in \{1, ..., R\}$, their site by $s(i) \in \{1, ..., S_{r(i)}\}$, and their epoch by $t(i) \in \{1, ..., T\}$. Their anticoagulation design vector is denoted by x_{Ci} and their antiviral design vector by x_{Ai}, their aspirin ineligibility by e_i, their age group by a_i, and oxygen requirement o_i, so that

$$\eta_i = x_{Ci}^{\mathsf{T}}\beta_C + x_{Ai}^{\mathsf{T}}\beta_A + \rho_{r(i)} + \xi_{r(i),s(i)} + \tau_{t(i)} + \omega_1 e_i + \omega_2 a_i + \omega_3 o_i,$$

was the linear predictor for the outcome for participant i.

For all models, the prior distribution on the linear components were

$$\beta_C \overset{\text{iid}}{\sim} \text{Normal}(0,1)$$
$$\beta_A \overset{\text{iid}}{\sim} \text{Normal}(0,1)$$
$$\rho_1 = 0, \rho_r \sim \text{Normal}(0,1), \quad r = 2, ..., R$$
$$\tau_1 = 0, \tau_t \sim \text{Normal}(\tau_{t-1}, \sigma_\tau^2), \quad t = 2, ..., T$$
$$\sigma_\tau \sim \text{Student-}t(3,0,1)$$
$$\xi_{r,s} \sim \text{Normal}(0, \sigma_{\xi_r}^2), \quad s = 1, ..., S_r, \quad r = 1, ..., R$$
$$\sigma_{\xi_r} \sim \text{Student-}t(3,0,1), \quad r = 1, ..., R$$
$$\omega_1 \sim \text{Normal}(0, 10^2)$$
$$\omega_2 \sim \text{Normal}(0, 2.5^2)$$
$$\omega_3 \sim \text{Normal}(0, 2.5^2).$$

For **binary outcomes**, $y_i \in \{0, 1\}$, the model was

$$\pi(\eta) = \text{logit}^{-1}(\beta_0 + \eta)$$
$$y_i \sim \text{Bernoulli}(\pi(\eta_i))$$

with $\beta_0 \sim \text{Normal}(0, 2.5^2)$.

For **ordinal outcomes** with K levels, $y_i \in \{1, ..., K\}$, the model was

$$\pi_k(\eta) = \begin{cases} 1 - \text{logit}^{-1}(\eta - \alpha_1) & k = 1 \\ \text{logit}^{-1}(\eta - \alpha_{k-1}) - \text{logit}^{-1}(\eta - \alpha_k) & k = 2, ..., K-1 \\ \text{logit}^{-1}(\eta - \alpha_{K-1}) & k = K \end{cases}$$
$$y_i \sim \text{Categorical}(\pi_k(\eta_i))$$

where $\alpha_k < \alpha_{k+1}$ for $k \in \{1, ..., K-2\}$ and $\pi(0) \sim \text{Dirichlet}(2/K, \cdots, 2/K)$.

For the **time-to-clinical-recovery outcome**, where $d_i \in \{1, ..., 28\}$ denotes the day of first event (or censoring at day 28) and $m \in \{0, 1, 2\}$ indicates event types (unrecovered, recovered, died), and $y_{id} = (y_{id0}, y_{id1}, y_{id2})$ with $y_{itm} \in \{0, 1\}$ indicates the status of patient i at day $d \leq d_i$, then the model was

$$\lambda_m(d, \eta) = \frac{\exp(\alpha_{dm} + \eta_m)}{1 + \sum_{l=1}^{M} \exp(\alpha_{dl} + \eta_l)}, \quad m = 1, 2$$
$$y_{id} \sim \text{Multinomial}\left(1, \left(1 - \sum_{l=1}^{2} \lambda_l(d, \eta_i), \lambda_1(d, \eta_i), \lambda_2(d, \eta_i)\right)\right), \quad d \leq d_i,$$

where $\eta = (\eta_1, \eta_2)$ contains the event-specific linear predictors with event-specific parameters in the same structure as previously introduced, and with priors

$$\begin{aligned} \alpha_{1m} &\sim \text{Normal}(0, 10^2) \\ \alpha_{dm} &\sim \text{Normal}(\alpha_{d-1,m}, \sigma_\alpha^2) \end{aligned}, \quad m = 1, 2,$$

on the event-specific baseline-hazard terms.

1.5 Trial Decision Criteria

As per the statistical appendix to the core protocol, the following decision quantities were of interest in the anticoagulation domain for the primary outcome model:

- **Superiority**: superiority was assessed using the posterior probability that the intervention has the lowest odds of the outcome amongst all interventions in the domain. If a single intervention had probability exceeding 0.99 superiority would be triggered for that intervention.
- **Effectiveness**: effectiveness was assessed relative to the low-dose arm as the posterior probability that the intervention reduces the odds of the outcome. If any intervention had probability exceeding 0.99 then effectiveness would be triggered for that intervention.
- **Futility**: futility was assessed relative to the low-dose arm as the posterior probability that the intervention reduces the odds of the outcome by no more than a factor of $1/1.1$. If any intervention had probability exceeding 0.95 than futility would be triggered for that intervention.
- **Equivalence**: equivalence was assessed relative to the low-dose arm as the posterior probability that the intervention alters the odds of the outcome by a factor bounded by $(1/1.1, 1.1)$.

2 Results

2.1 Study Population

2.1.1 Summary

At the time of database lock for the antiviral domain, 1,606 participants had been enrolled onto the study platform. Of these enrolees, 1,574 were randomised to the anticoagulation domain and 159 were randomised to the antiviral domain (127 to both domains, 32 to antiviral only, and 1,447 to anticoagulation only). The first participant was randomised on 2021-02-08, the last participant enrolled into the anticoagulation domain was randomised on 2022-03-29, and the last participant enrolled into the antiviral domain was randomised on 2022-08-04.

From the 1,606 enrolled participants, 18 withdrew consent for follow-up, leaving 1,588 participants with expected follow-up.

2.1.2 Analysis Sets

Table 2.1: Overview of the analysis sets used in this report.

Name	Definition
FAS-ITT	All participants who were randomised to at least one study domain. Participants will be analysed as randomised, irrespective of withdrawal from treatment, treatment compliance, or other protocol deviations.
ACS-ITT	Subset of FAS-ITT who were randomised to the anticoagulation domain.
AVS-ITT	Subset of FAS-ITT who were randomised to the antiviral domain.

Name	Definition
FAS-PP	All participants who were randomised to at least one study domain and satisfied platform, domain, and intervention protocol requirements.
ACS-PP	All participants who were randomised to the anticoagulation domain and satisfied platform, domain, and intervention protocol requirements.
AVS-PP	All participants who were randomised to the antiviral domain and satisfied platform, domain, and intervention protocol requirements.

The following sections summarise the distribution of treatment allocations for participants included in each of the above sets.

2.1.2.1 FAS-ITT

Table 2.2: Distribution of intervention assignments for participants in the FAS-ITT set. Brackets indicate the number of participants in that cell with missing primary outcome due to withdrawal from the study, loss-to-follow-up, or missing data.

	Antiviral			
Anticoagulation	Not randomised A	SoC	Nafamostat	Total
Not randomised C	0 (0)	18 (0)	14 (0)	32 (0)
Low	569 (19)	26 (0)	24 (2)	619 (21)
Intermediate	566 (13)	19 (0)	35 (1)	620 (14)
Low with aspirin	278 (6)	6 (0)	1 (0)	285 (6)
Therapeutic	35 (0)	4 (0)	11 (0)	50 (0)
Total	1448 (38)	73 (0)	85 (3)	1606 (41)

2.1.2.2 ACS-ITT

Table 2.3: Distribution of intervention assignments for participants in the ACS-ITT set. Brackets indicate the number of participants in that cell with missing primary outcome due to withdrawal from the study, loss-to-follow-up, or missing data.

| | Antiviral | | | |
Anticoagulation	Not randomised A	SoC	Nafamostat	Total
Low	569 (19)	26 (0)	24 (2)	619 (21)
Intermediate	566 (13)	19 (0)	35 (1)	620 (14)
Low with aspirin	278 (6)	6 (0)	1 (0)	285 (6)
Therapeutic	35 (0)	4 (0)	11 (0)	50 (0)
Total	1448 (38)	55 (0)	71 (3)	1574 (41)

2.1.2.3 AVS-ITT

Table 2.4: Distribution of intervention assignments for participants in the AVS-ITT set. Brackets indicate the number of participants in that cell with missing primary outcome due to withdrawal from the study, loss-to-follow-up, or missing data.

| | Antiviral | | |
Anticoagulation	SoC	Nafamostat	Total
Not randomised C	18 (0)	14 (0)	32 (0)
Low	26 (0)	24 (2)	50 (2)
Intermediate	19 (0)	35 (1)	54 (1)
Low with aspirin	6 (0)	1 (0)	7 (0)
Therapeutic	4 (0)	11 (0)	15 (0)
Total	73 (0)	85 (3)	158 (3)

2.1.2.4 FAS-PP

Table 2.5: Distribution of intervention assignments for participants in the FAS-PP set. Brackets indicate the number of participants in that cell with missing primary outcome due to withdrawal from the study, loss-to-follow-up, or missing data.

| | Antiviral | | | |
Anticoagulation	Not randomised A	SoC	Nafamostat	Total
Not randomised C	0 (0)	16 (0)	11 (0)	27 (0)
Low	554 (12)	24 (0)	16 (0)	594 (12)
Intermediate	553 (7)	18 (0)	29 (0)	600 (7)
Low with aspirin	267 (3)	6 (0)	1 (0)	274 (3)
Therapeutic	34 (0)	2 (0)	8 (0)	44 (0)
Total	1408 (22)	66 (0)	65 (0)	1539 (22)

2.1.2.5 ACS-PP

Table 2.6: Distribution of intervention assignments for participants in the ACS-PP set. Brackets indicate the number of participants in that cell with missing primary outcome due to withdrawal from the study, loss-to-follow-up, or missing data.

| | Antiviral | | | |
Anticoagulation	Not randomised A	SoC	Nafamostat	Total
Low	554 (12)	24 (0)	16 (0)	594 (12)
Intermediate	553 (7)	18 (0)	29 (0)	600 (7)
Low with aspirin	267 (3)	6 (0)	1 (0)	274 (3)
Therapeutic	34 (0)	2 (0)	8 (0)	44 (0)
Total	1408 (22)	50 (0)	54 (0)	1512 (22)

2.1.2.6 AVS-PP

Table 2.7: Distribution of intervention assignments for participants in the AVS-PP set. Brackets indicate the number of participants in that cell with missing primary outcome due to withdrawal from the study, loss-to-follow-up, or missing data.

| | Antiviral | | |
Anticoagulation	SoC	Nafamostat	Total
Not randomised C	16 (0)	11 (0)	27 (0)
Low	24 (0)	16 (0)	40 (0)
Intermediate	18 (0)	29 (0)	47 (0)
Low with aspirin	6 (0)	1 (0)	7 (0)
Therapeutic	2 (0)	8 (0)	10 (0)
Total	66 (0)	65 (0)	131 (0)

2.1.3 Disposition

Of the 1,606 participants randomised to the trial, 18 withdrew consent for follow-up (16 on study day 1 and 2 on study day 2) leaving 1,588 participants continuing to study day 28. The analyses and summaries included in this report exclude data on participants who withdrew consent for follow-up.

Platform and domain specific flow diagrams is shown in in Figure 2.1 and Figure 2.2.

Figure 2.3 presents overall platform enrolments by calendar time with timing of intervention availabilities and interim analyses. Due to an insufficient number of participants on the therapeutic anticoagulation arm, the initial allocation ratios were not changed during recruitment to the anticoagulation domain. Therefore, the only trial adaptations which occurred were the cessation of the standard dose plus aspirin intervention in the anticoagulation domain, the opening of the antiviral domain, and the introduction of the therapeutic dose intervention into the anticoagulation domain. Despite this, the timing of interim analyses are indicated on the Figures.

2.1.4 Intervention Allocations

Response adaptive randomisation (RAR) was never activated in the anticoagulation domain. This was due to the therapeutic intervention never exceeding the minimum sample size of 50, and the fixed allocation to control. Therefore, target allocations to the interventions were uniform across all available interventions from trial start to trial closure. However, the available interventions did change over time and availability varied by region and site. Similarly, RAR was never activated in the antiviral domain due to insufficient sample size.

The following figures summarise treatment allocations by country, site, and calendar time.

```
                    ┌─────────────────────────────┐
                    │  Screened for platform      │
                    │  eligibility                │
                    │  2,254                      │
                    └─────────────────────────────┘
                                  │
                                  │        ┌──────────────────────────────────────────────────┐
                                  │        │ 648  Ineligible for platform:                    │
                                  │        │   179 Did not consent                            │
                                  │        │   174 Not in the patients best interests         │
                                  │        │    68 No eligible domains                        │
                                  │        │    59 Not committed to active treatment          │
                                  │        │    43 First positive test - over 14 days ago     │
                                  │────────▶    31 No signs or symptoms                        │
                                  │        │    31 First symptoms - over 14 days ago          │
                                  │        │    28 SARS-CoV-2 not confirmed by test           │
                                  │        │    18 Receiving acute intensive respiratory      │
                                  │        │         support                                  │
                                  │        │     6 Did not consent to any domains             │
                                  │        │     6 Expired platform pending                   │
                                  │        │     4 Previously participated in the trial       │
                                  │        │     1 Pregnant patients not enrolled at this     │
                                  │        │         hospital                                 │
                                  │        └──────────────────────────────────────────────────┘
                                  │
```

$\dagger$Participants may meet more than one exclusion criteria
```
25 Ineligible for anticoagulation domain$^\dagger$:
   18 Domain unavailable
   12 Did not consent to domain
    1 Clinician to commence therapeutic anticoagulation
    1 eGFR< 15ml/min/1.73m$^2$
40 Ineligible for aspirin intervention$^\dagger$
   40 Receiving an antiplatelet agent
    1 Hypersensitivity to aspirin
```

Enrolled into platform
1,606

Randomised to anticoagulation domain
1,574

| Low-dose 619 | Intermediate-dose 620 | Low-dose with aspirin 285 | Therapeutic-dose 50 |

21 Excluded:
  9 Withdrew follow-up
  12 Missing primary outcome

14 Excluded:
  7 Withdrew follow-up
  7 Missing primary outcome

6 Excluded:
  2 Withdrew follow-up
  4 Missing primary outcome

0 Excluded:
  0 Withdrew follow-up
  0 Missing primary outcome

Included in primary analysis 598

Included in primary analysis 606

Included in primary analysis 279

Included in primary analysis 50

Figure 2.1: Combined domain flowchart for anticoagulation.

Figure 2.2: Combined domain flowchart for antiviral.

Figure 2.3: Overall enrolment to the study by domain with intervention availability. Vertical dashed lines indicate timing of interim analyses.

Figure 2.4: Intervention allocations by calendar time (month) for anticoagulation domain.

Figure 2.5: Intervention allocations by calendar time (month) for antiviral domain (excludes India as antiviral domain not available).

Figure 2.6: Intervention allocations by study site for anticoagulation domain.

Figure 2.7: Intervention allocations by study site for antiviral domain.

2.1.5 Compliance

There were two participants who received the wrong dosage (according to the antiviral domain specific appendix) on at least one day given their baseline weight:

- One participant reportedly had 3 days of 500 mg/day instead of 350 mg/day (baseline weight of 65 kg). This participant was determined to not be per-protocol.
- Another participant reportedly had 2 days of 350 mg/day instead of 250 mg/day (baseline weight of 60 kg). This participant was determined to be per-protocol.

Figure 2.8 presents the distribution of Nafamostat infusion duration for each study day amongst participants assigned to receive Nafamostat. Table 2.8 presents summaries of treatment compliance for participants assigned to Nafamostat. Table 2.9 outlines the number of participants who were not per-protocol and the associated reason by their assigned antiviral intervention.

Figure 2.8: Distribution of Nafamostat infusion duration by study day (1 to 8) amongst participants assigned to Nafamostat.

Table 2.8: Compliance to Nafamostat.

Summary	Value
Days on study treatment	
Median (IQR)	5 (3 - 7)
Min, Max	0, 8
Missing	0
Days off study treatment	
Median (IQR)	0 (0 - 1)
Min, Max	0, 7
Missing	0
Total hours receiving infusion	
Median (IQR)	89.7 (57.8 - 138.8)
Min, Max	0.0, 176.6
Missing	0
Hours per day on infusion	
Median (IQR)	17.6 (14.3 - 19.7)
Min, Max	0.0, 22.1
Missing	0
Proportion of days admitted to hospital with infusion $\geq$ 21/24 hours[1]	
Median (IQR)	0.55 (0.50 - 0.71)
Min, Max	0.00, 0.88
Missing	0
Days with 21/24 hours infusion	
Median (IQR)	3 (2 - 5)
Min, Max	0, 7
Missing	0
Days without 21/24 hours infusion	
Median (IQR)	0 (0 - 1)
Min, Max	0, 7
Missing	0

Days on study treatment is any part day on drug.

Days off treatment is any day when no Nafamostat was administered.

Days without 21/24 excludes day 1 and day of discharge.

[1] up to 7 days while hospitalised

Table 2.9: Per-protocol status for antiviral domain

Antiviral	Per Protocol?	Reason	Count
Standard of care	Not Per Protocol	withdrawn from antiviral & anticoagulation treatment (by patient)	1
Standard of care	Per Protocol	NA	72
Nafamostat	Not Per Protocol	>3 hr disruption	9
Nafamostat	Not Per Protocol	withdrawn from antiviral treatment (by patient)	7
Nafamostat	Not Per Protocol	>3 hr disruption. Dose was charted incorrectly for patient's weight on days 1 to 4.	1
Nafamostat	Not Per Protocol	Patient received more than allocated dose (up to day 9) with a disruption on day 7 of >3hrs	1
Nafamostat	Not Per Protocol	withdrawn from antiviral treatment (by treating clinician due to nausea and vomitting)	1
Nafamostat	Per Protocol	NA	62
Nafamostat	Per Protocol	withdrawn from antiviral & anticoagulation treatment (by treating clinician due to concerns about haemoptysis)	1

2.1.6 Baseline Characteristics

The following baseline summaries exclude participants who withdrew consent for follow-up.

2.1.6.1 Demographics

The age distribution of participants are presented in Figure 2.9, Figure 2.10, and Figure 2.11.

Figure 2.9: Distribution of age amongst participants randomised in the trial.

Baseline demographics stratified by anticoagulation interventions are reported in Table 2.10 and by antiviral interventions in Table 2.11.

Figure 2.10: Distribution of age amongst participants randomised to the anticoagulation domain.

Figure 2.11: Distribution of age amongst participants randomised to the antiviral domain.

Table 2.10: Baseline demographics for participants randomised to the anticoagulation domain.

Variable	Anticoagulation				Overall
	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	
	(n = 610)	(n = 613)	(n = 283)	(n = 50)	(n = 1556)
Age (years), Median (IQR)	48 (37, 60)	48 (37, 61)	50 (38, 62)	58 (46, 69)	49 (37, 61)
Country					
India, n (%)	493 (81)	516 (84)	275 (97)	4 (8)	1288 (83)
Australia, n (%)	49 (8)	59 (10)	7 (2)	11 (22)	126 (8)
Nepal, n (%)	56 (9)	31 (5)	0 (0)	31 (62)	118 (8)
New Zealand, n (%)	12 (2)	7 (1)	1 (0)	4 (8)	24 (2)
Sex					
Male, n (%)	354 (58)	387 (63)	157 (55)	25 (50)	923 (59)
Female, n (%)	256 (42)	226 (37)	126 (45)	25 (50)	633 (41)
Weight (kg)					
Median, (IQR)	68 (62, 76)	70 (62, 77)	68 (62, 76)	66 (57, 80)	69 (62, 76)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Vaccinated[1]					
Yes, n (%)	191 (31)	220 (36)	42 (15)	27 (54)	480 (31)
Missing, n (%)	32 (5)	22 (4)	29 (10)	0 (0)	83 (5)
Ethnicity					
Indian, n (%)	494 (81)	518 (85)	275 (97)	4 (8)	1291 (83)
European, n (%)	21 (3)	18 (3)	4 (1)	4 (8)	47 (3)
Asian, n (%)	20 (3)	12 (2)	1 (0)	10 (20)	43 (3)
Pacific Islander, n (%)	13 (2)	12 (2)	2 (1)	3 (6)	30 (2)
Middle Eastern, n (%)	11 (2)	11 (2)	0 (0)	0 (0)	22 (1)
Maori, n (%)	3 (0)	4 (1)	0 (0)	3 (6)	10 (1)
African, n (%)	1 (0)	0 (0)	1 (0)	0 (0)	2 (0)
Aboriginal, n (%)	0 (0)	1 (0)	0 (0)	1 (2)	2 (0)
Latin American, n (%)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)
Other, n (%)	45 (7)	28 (5)	0 (0)	23 (46)	96 (6)
Unknown, n (%)	8 (1)	9 (1)	0 (0)	3 (6)	20 (1)
Smoking					
Current, n (%)	17 (3)	21 (3)	3 (1)	5 (10)	46 (3)
Former, n (%)	74 (12)	53 (9)	15 (5)	14 (28)	156 (10)
Never, n (%)	519 (85)	539 (88)	265 (94)	31 (62)	1354 (87)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

[1] Site LUD did not have ethics approval for collection of vaccination status.

Table 2.11: Baseline demographics for participants randomised to the antiviral domain.

| Variable | Antiviral | | Overall |
| | Standard of care | Nafamostat | |
	(n = 73)	(n = 82)	(n = 155)
Age (years), Median (IQR)	46 (37, 60)	44 (34, 60)	45 (35, 60)
Country			
India, n (%)	0 (0)	0 (0)	0 (0)
Australia, n (%)	65 (89)	67 (82)	132 (85)
Nepal, n (%)	2 (3)	3 (4)	5 (3)
New Zealand, n (%)	6 (8)	12 (15)	18 (12)
Sex			
Male, n (%)	39 (53)	56 (68)	95 (61)
Female, n (%)	34 (47)	26 (32)	60 (39)
Weight (kg)			
Median, (IQR)	90 (70, 106)	90 (79, 110)	90 (78, 108)
Missing, n (%)	0 (0)	0 (0)	0 (0)
Vaccinated[1]			
Yes, n (%)	27 (37)	31 (38)	58 (37)
Missing, n (%)	7 (10)	1 (1)	8 (5)
Ethnicity			
Indian, n (%)	1 (1)	1 (1)	2 (1)
European, n (%)	18 (25)	27 (33)	45 (29)
Asian, n (%)	6 (8)	6 (7)	12 (8)
Pacific Islander, n (%)	12 (16)	12 (15)	24 (15)
Middle Eastern, n (%)	9 (12)	11 (13)	20 (13)
Maori, n (%)	1 (1)	7 (9)	8 (5)
African, n (%)	2 (3)	0 (0)	2 (1)
Aboriginal, n (%)	3 (4)	1 (1)	4 (3)
Latin American, n (%)	1 (1)	0 (0)	1 (1)
Other, n (%)	6 (8)	9 (11)	15 (10)
Unknown, n (%)	17 (23)	11 (13)	28 (18)
Smoking			
Current, n (%)	8 (11)	12 (15)	20 (13)
Former, n (%)	22 (30)	16 (20)	38 (25)
Never, n (%)	43 (59)	54 (66)	97 (63)
Missing, n (%)	0 (0)	0 (0)	0 (0)

[1] Site LUD did not have ethics approval for collection of vaccination status.

2.1.6.2 Co-morbidities

Baseline co-morbidities stratified by anticoagulation interventions are reported in Table 2.12 and to by antiviral interventions in Table 2.13.

Table 2.12: Baseline comorbidities for participants randomised to the anticoagulation domain.

Comorbidity	Anticoagulation				Overall (n = 1556)
	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	
None, n (%)	364 (60)	378 (62)	166 (59)	19 (38)	927 (60)
Hypertension, n (%)	147 (24)	140 (23)	68 (24)	14 (28)	369 (24)
Diabetes, n (%)	140 (23)	139 (23)	78 (28)	11 (22)	368 (24)
Obesity, n (%)	23 (4)	22 (4)	3 (1)	5 (10)	53 (3)
Asthma, n (%)	19 (3)	16 (3)	6 (2)	4 (8)	45 (3)
Chronic lung disease, n (%)	16 (3)	13 (2)	1 (0)	7 (14)	37 (2)
Chronic cardiac disease, n (%)	11 (2)	15 (2)	1 (0)	2 (4)	29 (2)
Obstructive sleep apnoea, n (%)	3 (0)	2 (0)	2 (1)	0 (0)	7 (0)
Iatrogenic immunosuppression, n (%)	1 (0)	6 (1)	0 (0)	0 (0)	7 (0)
Chronic kidney disease, n (%)	0 (0)	5 (1)	1 (0)	0 (0)	6 (0)
Malignant neoplasm, n (%)	1 (0)	2 (0)	0 (0)	1 (2)	4 (0)
Moderate or severe liver disease, n (%)	2 (0)	1 (0)	0 (0)	0 (0)	3 (0)
Dialysis, n (%)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)
HIV infection, n (%)	1 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Dementia, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Table 2.13: Baseline comorbidities for participants randomised to the antiviral domain.

Comorbidity	Antiviral		Overall (n = 155)
	Standard of care (n = 73)	Nafamostat (n = 82)	
None, n (%)	31 (42)	34 (41)	65 (42)
Obesity, n (%)	19 (26)	22 (27)	41 (26)
Hypertension, n (%)	16 (22)	17 (21)	33 (21)
Diabetes, n (%)	16 (22)	15 (18)	31 (20)
Asthma, n (%)	10 (14)	10 (12)	20 (13)
Chronic lung disease, n (%)	7 (10)	6 (7)	13 (8)
Chronic cardiac disease, n (%)	3 (4)	6 (7)	9 (6)
Iatrogenic immunosuppression, n (%)	2 (3)	4 (5)	6 (4)
Obstructive sleep apnoea, n (%)	3 (4)	2 (2)	5 (3)
Chronic kidney disease, n (%)	2 (3)	2 (2)	4 (3)
Malignant neoplasm, n (%)	1 (1)	2 (2)	3 (2)
Dialysis, n (%)	0 (0)	0 (0)	0 (0)
Moderate or severe liver disease, n (%)	0 (0)	0 (0)	0 (0)
Dementia, n (%)	0 (0)	0 (0)	0 (0)
HIV infection, n (%)	0 (0)	0 (0)	0 (0)
Missing, n (%)	0 (0)	0 (0)	0 (0)

2.1.6.3 Prognostics

Baseline prognostics stratified by anticoagulation interventions are reported in Table 2.14 and to by antiviral interventions in Table 2.15.

Table 2.14: Baseline prognostics for participants randomised to the anticoagulation domain.

	Anticoagulation				Overall (n = 1556)
Variable	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	
Was the patient on room air for any of the preceding 24 hours?					
Yes, n (%)	460 (75)	460 (75)	224 (79)	39 (78)	1183 (76)
Missing, n (%)	8 (1)	9 (1)	8 (3)	0 (0)	25 (2)
Was the patient's GCS < 15?					
Yes, n (%)	63 (10)	65 (11)	6 (2)	2 (4)	136 (9)
Missing, n (%)	125 (20)	135 (22)	60 (21)	0 (0)	320 (21)
Peripheral oxygen saturation (SpO2) on room air (Lowest)					
Median (IQR)	95 (94, 97)	96 (94, 97)	96 (94, 97)	94 (92, 96)	96 (94, 97)
Missing, n (%)	150 (25)	153 (25)	59 (21)	11 (22)	373 (24)
Highest respiratory rate (breaths/minute)					
Median (IQR)	22 (21, 25)	22 (21, 26)	22 (20, 26)	22 (20, 24)	22 (21, 26)
Missing, n (%)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)
Highest recorded Urea in the last 24 hours (mmol/L)					
Median (IQR)	4 (3, 5)	5 (4, 6)	4 (3, 6)	4 (3, 6)	4 (3, 6)
Missing, n (%)	30 (5)	33 (5)	16 (6)	1 (2)	80 (5)
Highest recorded CRP in the last 24 hours (mg/L)					
Median (IQR)	199 (61, 400)	200 (67, 395)	300 (135, 516)	71 (53, 175)	220 (68, 410)
Missing, n (%)	74 (12)	59 (10)	18 (6)	29 (58)	180 (12)
APTT[1]					
Median (IQR)	33 (29, 36)	33 (30, 36)	32 (28, 37)	33 (28, 38)	33 (29, 36)
Missing, n (%)	430 (70)	439 (72)	195 (69)	35 (70)	1099 (71)
INR[1]					
Mean (SD)	1.19 (0.39)	1.23 (0.58)	1.32 (1.34)	1.12 (0.18)	1.23 (0.72)
Missing, n (%)	103 (17)	105 (17)	47 (17)	7 (14)	262 (17)
Fibrinogen[1] (g/L)					
Mean (SD)	5.19 (2.01)	5.20 (1.60)	4.75 (1.40)	6.49 (1.52)	5.14 (1.71)
Missing, n (%)	564 (92)	555 (91)	243 (86)	42 (84)	1404 (90)
Prothrombin time[1] (sec)					
Median (IQR)	14 (13, 17)	14 (13, 17)	15 (13, 16)	13 (12, 14)	14 (13, 16)
Missing, n (%)	193 (32)	204 (33)	116 (41)	10 (20)	523 (34)
Taking aspirin					
Yes, n (%)	20 (3)	25 (4)	2 (1)	3 (6)	50 (3)
Missing, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Time from onset of symptoms to hospitalisation					
Median (IQR)	5 (3, 7)	5 (3, 6)	4 (2, 6)	4 (3, 6)	4 (3, 6)
Time from hospitalisation to randomisation					
Median (IQR)	1 (0, 2)	1 (0, 2)	1 (1, 2)	1 (1, 1)	1 (0, 2)
D-dimer					
Test performed, n(%)	494 (81)	514 (84)	247 (87)	17 (34)	1272 (82)
Out of range, n(%)	182 (37)	177 (35)	63 (26)	10 (59)	432 (34)

[1] For APTT, INR, Fibrinogen, and Prothrombin only at least one required.

Table 2.15: Baseline prognostics for participants randomised to the antiviral domain.

| Variable | Antiviral | | Overall (n = 155) |
	Standard of care (n = 73)	Nafamostat (n = 82)	
Was the patient on room air for any of the preceding 24 hours?			
Yes, n (%)	48 (66)	42 (51)	90 (58)
Missing, n (%)	0 (0)	0 (0)	0 (0)
Was the patient's GCS < 15?			
Yes, n (%)	5 (7)	4 (5)	9 (6)
Missing, n (%)	1 (1)	0 (0)	1 (1)
Peripheral oxygen saturation (SpO2) on room air (Lowest)			
Median (IQR)	93 (90, 95)	93 (92, 95)	93 (91, 95)
Missing, n (%)	25 (34)	40 (49)	65 (42)
Highest respiratory rate (breaths/minute)			
Median (IQR)	24 (20, 28)	24 (21, 28)	24 (21, 28)
Missing, n (%)	1 (1)	0 (0)	1 (1)
Highest recorded Urea in the last 24 hours (mmol/L)			
Median (IQR)	5 (4, 7)	5 (4, 7)	5 (4, 7)
Missing, n (%)	4 (5)	4 (5)	8 (5)
Highest recorded CRP in the last 24 hours (mg/L)			
Median (IQR)	68 (32, 113)	53 (28, 74)	58 (28, 102)
Missing, n (%)	5 (7)	11 (13)	16 (10)
APTT[1]			
Median (IQR)	33 (31, 36)	33 (30, 36)	33 (30, 36)
Missing, n (%)	23 (32)	20 (24)	43 (28)
INR[1]			
Mean (SD)	1.09 (0.09)	1.07 (0.11)	1.08 (0.10)
Missing, n (%)	25 (34)	26 (32)	51 (33)
Fibrinogen[1] (g/L)			
Mean (SD)	5.76 (2.08)	5.62 (1.56)	5.68 (1.79)
Missing, n (%)	42 (58)	42 (51)	84 (54)
Prothrombin time[1] (sec)			
Median (IQR)	13 (13, 14)	13 (13, 14)	13 (13, 14)
Missing, n (%)	30 (41)	29 (35)	59 (38)
Taking aspirin			
Yes, n (%)	4 (5)	8 (10)	12 (8)
Missing, n (%)	18 (25)	14 (17)	32 (21)
Time from onset of symptoms to hospitalisation			
Median (IQR)	6 (4, 8)	6 (4, 8)	6 (4, 8)
Time from hospitalisation to randomisation			
Median (IQR)	1 (1, 2)	1 (1, 2)	1 (1, 2)
D-dimer			
Test performed, n(%)	54 (74)	51 (62)	105 (68)
Out of range, n(%)	35 (65)	32 (64)	67 (64)

[1] For APTT, INR, Fibrinogen, and Prothrombin only at least one required.

The relative timing (in days) of hospitalisation, symptom onset, randomisation, and first positive test are presented in Figure 2.12.

Figure 2.12: Days between events for hospitalisation, randomisation, symptom onset, and first positive test.

2.1.6.4 Overall Summary

Table 2.16: Baseline summary for participants randomised to the antiviral domain.

Variable	Standard of care (n = 73)	Nafamostat (n = 82)	All participants (n = 155)
Age – yr	46 (37, 60)	44 (34, 60)	45 (35, 60)
Male sex	39 (53)	56 (68)	95 (61)
Country			
Australia	65 (89)	67 (82)	132 (85)
New Zealand	6 (8)	12 (15)	18 (12)
Nepal	2 (3)	3 (4)	5 (3)
Ethnicity			
European	18 (25)	27 (33)	45 (29)
Pacific peoples or Maori	13 (18)	19 (23)	32 (21)
Middle Eastern	9 (12)	11 (13)	20 (13)
Asian	6 (8)	6 (7)	12 (8)
Aboriginal	3 (4)	1 (1)	4 (3)
Indian	1 (1)	1 (1)	2 (1)
African	2 (3)	0 (0)	2 (1)
Latin American	1 (1)	0 (0)	1 (1)
Other/unknown	21 (29)	19 (23)	40 (26)
Weight – kg	90 (70, 106)	90 (79, 110)	90 (78, 108)
Vaccinated – no./total no.	27/66 (41)	31/81 (38)	58/147 (39)
Co-morbidities			
Obesity	19 (26)	22 (27)	41 (26)
Hypertension	16 (22)	17 (21)	33 (21)
Diabetes	16 (22)	15 (18)	31 (20)
Asthma	10 (14)	10 (12)	20 (13)
Chronic lung disease	7 (10)	6 (7)	13 (8)
Chronic cardiac disease	3 (4)	6 (7)	9 (6)
No. of days			
Onset of symptoms to hospitalisation	8 (5, 10)	7 (5, 10)	8 (5, 10)
Hospitalisation to randomisation	1 (1, 2)	1 (1, 2)	1 (1, 2)
Any time breathing ambient air in past 24 hours	48 (66)	42 (51)	90 (58)
Lowest SpO2 while breathing ambient air	93 (90, 95)	93 (92, 95)	93 (91, 95)
Highest respiratory rate in past 24 hours	24 (20, 28)	24 (21, 28)	24 (21, 28)
Glasgow coma score < 15	5 (7)	4 (5)	9 (6)
Lab values			
CRP – mg/L	68 (32, 113)	53 (28, 74)	58 (28, 102)
CRP Patients evaluated	68 (93)	71 (87)	139 (90)
D-dimer > upper limit normal	35 (65)	32 (64)	67 (64)
D-dimer Patients evaluated	54 (74)	50 (61)	104 (67)
APTT – s	33 (31, 36)	33 (30, 36)	33 (30, 36)
APTT Patients evaluated	50 (68)	62 (76)	112 (72)
Internation normlised ratio (SD)	1.09 (0.09)	1.07 (0.11)	1.08 (0.10)
INR Patients evaluated	48 (66)	56 (68)	104 (67)

2.1.7 Discharge Summaries

2.1.7.1 Drugs Received During Hospital Stay

There were 18 participants without a discharge record (due to withdrawal of consent for follow-up). For the continuing participants, the other medications received during their hospital stay are reported in Table 2.17 and Table 2.18.

Table 2.17: Drugs received during hospital stay for participants randomised to the anticoagulation domain.

Drug received	Anticoagulation				Overall (n = 1556)
	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	
Antibacterial drugs, n (%)	449 (74)	443 (72)	231 (82)	38 (76)	1161 (75)
Antivirals					
No antiviral, n (%)	125 (20)	120 (20)	44 (16)	39 (78)	328 (21)
Camostat, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Favipiravir, n (%)	97 (16)	100 (16)	34 (12)	0 (0)	231 (15)
Ivermectin, n (%)	201 (33)	200 (33)	91 (32)	0 (0)	492 (32)
Remdesivir, n (%)	286 (47)	289 (47)	169 (60)	10 (20)	754 (48)
Other antiviral, n (%)	3 (0)	1 (0)	1 (0)	0 (0)	5 (0)
Immunomodulatory					
No immunomodulatory, n (%)	60 (10)	68 (11)	38 (13)	6 (12)	172 (11)
Anakinra, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Corticosteroids, n (%)	396 (65)	388 (63)	183 (65)	37 (74)	1004 (65)
Sarilumab, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Azithromycin, n (%)	105 (17)	108 (18)	38 (13)	5 (10)	256 (16)
Tocilizumab, n (%)	12 (2)	11 (2)	5 (2)	2 (4)	30 (2)
Baricitinib, n (%)	36 (6)	50 (8)	11 (4)	6 (12)	103 (7)
Ruxolitinib, n (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Tofacitinib, n (%)	11 (2)	13 (2)	5 (2)	0 (0)	29 (2)
Zinc, n (%)	388 (64)	394 (64)	173 (61)	13 (26)	968 (62)
Other immunomodulatory, n (%)	20 (3)	20 (3)	11 (4)	1 (2)	52 (3)

Table 2.18: Drugs received during hospital stay for participants randomised to the anti-viral domain.

Drug received	Antiviral		Overall (n = 155)
	Standard of care (n = 73)	Nafamostat (n = 82)	
Antibacterial drugs, n (%)	33 (45)	38 (46)	71 (46)
Antivirals			
No antiviral, n (%)	28 (38)	36 (44)	64 (41)
Camostat, n (%)	0 (0)	0 (0)	0 (0)
Favipiravir, n (%)	0 (0)	0 (0)	0 (0)
Ivermectin, n (%)	1 (1)	1 (1)	2 (1)
Remdesivir, n (%)	39 (53)	39 (48)	78 (50)
Other antiviral, n (%)	5 (7)	3 (4)	8 (5)
Immunomodulatory			
No immunomodulatory, n (%)	10 (14)	9 (11)	19 (12)
Anakinra, n (%)	0 (0)	0 (0)	0 (0)
Corticosteroids, n (%)	55 (75)	70 (85)	125 (81)
Sarilumab, n (%)	0 (0)	0 (0)	0 (0)
Azithromycin, n (%)	6 (8)	9 (11)	15 (10)
Tocilizumab, n (%)	5 (7)	3 (4)	8 (5)
Baricitinib, n (%)	24 (33)	38 (46)	62 (40)
Ruxolitinib, n (%)	0 (0)	0 (0)	0 (0)
Tofacitinib, n (%)	0 (0)	0 (0)	0 (0)
Zinc, n (%)	1 (1)	2 (2)	3 (2)
Other immunomodulatory, n (%)	3 (4)	3 (4)	6 (4)

2.2 Primary Outcome

2.2.1 Descriptive

The primary outcome is a composite comprised of:

- day 28 mortality
- vasopressor/inotropic support within first 28 days
- new intensive respiratory support within first 28 days.

The definition also allowed for patients who had unknown day 28 status, but were discharged against medical advice (DAMA) and designated as likely to die within 28 days. However, no participants met this criteria (all cases of DAMA and likely to die within 28 days had known day 28 status).

The proportion of participants who met the primary outcome, and rates of missingness, are reported in Table 2.19 and Table 2.20.

A breakdown of the composite, including missingness by component is reported for ACS-ITT and AVS-ITT in Table 2.21 and Table 2.22 respectively. Missingness was predominantly due to unknown patient status at study day 28.

A breakdown of the composite by timing of interim analyses is reported in Table 2.23.

A summary of the primary outcome by each of the baseline covariates pre-specified to be included in the primary model (or as pre-specified subgroup analyses) are presented in the appendix (Section 3.1.1).

Table 2.19: Summary of primary composite outcome by anticoagulation treatment group.

n (%)	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	610	613	283	50	1556
Outcome missing	12 (2.0)	7 (1.1)	4 (1.4)	0 (0.0)	23 (1.5)
Outcome observed	598 (98.0)	606 (98.9)	279 (98.6)	50 (100.0)	1533 (98.5)
Met primary outcome	35 (5.9)	25 (4.1)	20 (7.2)	7 (14.0)	87 (5.7)

Table 2.20: Summary of primary composite outcome by antiviral treatment group.

n (%)	Standard of care	Nafamostat	Overall
Randomised	73	82	155
Outcome missing	0 (0.0)	0 (0.0)	0 (0.0)
Outcome observed	73 (100.0)	82 (100.0)	155 (100.0)
Met primary outcome	8 (11.0)	4 (4.9)	12 (7.7)

Table 2.21: Breakdown of primary composite outcome by anticoagulation treatment group, ACS-ITT.

Outcome	Breakdown	Not randomised (n = 32)	Low dose (n = 610)	Intermediate dose (n = 613)	Low dose with aspirin (n = 283)	Therapeutic dose (n = 50)	Overall (n = 1588)
Primary outcome							
No		28 (87.5)	563 (92.3)	581 (94.8)	259 (91.5)	43 (86.0)	1474 (92.8)
Yes		4 (12.5)	35 (5.7)	25 (4.1)	20 (7.1)	7 (14.0)	91 (5.7)
Unknown	Total	0 (0.0)	12 (2.0)	7 (1.1)	4 (1.4)	0 (0.0)	23 (1.4)
	Day 28 status	0 (0.0)	11 (1.8)	5 (0.8)	2 (0.7)	0 (0.0)	18 (1.1)
	Vasopressor/inotropes	0 (0.0)	1 (0.2)	2 (0.3)	2 (0.7)	0 (0.0)	5 (0.3)
Total		32 (100.0)	610 (100.0)	613 (100.0)	283 (100.0)	50 (100.0)	1588 (100.0)
Mortality							
Alive at day 28		32 (100.0)	579 (94.9)	593 (96.7)	271 (95.8)	44 (88.0)	1519 (95.7)
Death within 28 days	Total	0 (0.0)	19 (3.1)	15 (2.4)	10 (3.5)	6 (12.0)	50 (3.1)
	Prior to discharge	0 (0.0)	15 (2.5)	11 (1.8)	10 (3.5)	4 (8.0)	40 (2.5)
	Post-discharge	0 (0.0)	4 (0.7)	4 (0.7)	0 (0.0)	2 (4.0)	10 (0.6)
Unknown		0 (0.0)	12 (2.0)	5 (0.8)	2 (0.7)	0 (0.0)	19 (1.2)
Total		32 (100.0)	610 (100.0)	613 (100.0)	283 (100.0)	50 (100.0)	1588 (100.0)
Vasopressor/inotropes							
Not required		31 (96.9)	592 (97.0)	599 (97.7)	273 (96.5)	48 (96.0)	1543 (97.2)
Use within 28 days	Total	1 (3.1)	6 (1.0)	6 (1.0)	6 (2.1)	2 (4.0)	21 (1.3)
	Prior to discharge	1 (3.1)	5 (0.8)	6 (1.0)	6 (2.1)	2 (4.0)	20 (1.3)
	Post-discharge	0 (0.0)	2 (0.3)	0 (0.0)	0 (0.0)	1 (2.0)	3 (0.2)
Unknown		0 (0.0)	12 (2.0)	8 (1.3)	4 (1.4)	0 (0.0)	24 (1.5)
Total		32 (100.0)	610 (100.0)	613 (100.0)	283 (100.0)	50 (100.0)	1588 (100.0)
Ventilation							
Not required		28 (87.5)	564 (92.5)	584 (95.3)	263 (92.9)	43 (86.0)	1482 (93.3)
Use within 28 days	Total	4 (12.5)	35 (5.7)	24 (3.9)	18 (6.4)	7 (14.0)	88 (5.5)
	Prior to discharge	4 (12.5)	29 (4.8)	19 (3.1)	13 (4.6)	5 (10.0)	70 (4.4)
	Post-discharge	0 (0.0)	6 (1.0)	5 (0.8)	5 (1.8)	2 (4.0)	18 (1.1)
Unknown		0 (0.0)	11 (1.8)	5 (0.8)	2 (0.7)	0 (0.0)	18 (1.1)
Total		32 (100.0)	610 (100.0)	613 (100.0)	283 (100.0)	50 (100.0)	1588 (100.0)

Table 2.22: Breakdown of primary composite outcome by antiviral treatment group, AVS-ITT.

| Outcome | Breakdown | Antiviral | | | Overall |
		Not randomised to antiviral (n = 1433)	Standard of care (n = 73)	Nafamostat (n = 82)	(n = 1588)
Primary outcome					
No		1331 (92.9)	65 (89.0)	78 (95.1)	1474 (92.8)
Yes		79 (5.5)	8 (11.0)	4 (4.9)	91 (5.7)
Unknown	Total	23 (1.6)	0 (0.0)	0 (0.0)	23 (1.4)
	Day 28 status	18 (1.3)	0 (0.0)	0 (0.0)	18 (1.1)
	Vasopressor/inotropes	5 (0.3)	0 (0.0)	0 (0.0)	5 (0.3)
Total		1433 (100.0)	73 (100.0)	82 (100.0)	1588 (100.0)
Mortality					
Alive at day 28		1364 (95.2)	73 (100.0)	82 (100.0)	1519 (95.7)
Death within 28 days	Total	50 (3.5)	0 (0.0)	0 (0.0)	50 (3.1)
	Prior to discharge	40 (2.8)	0 (0.0)	0 (0.0)	40 (2.5)
	Post-discharge	10 (0.7)	0 (0.0)	0 (0.0)	10 (0.6)
Unknown		19 (1.3)	0 (0.0)	0 (0.0)	19 (1.2)
Total		1433 (100.0)	73 (100.0)	82 (100.0)	1588 (100.0)
Vasopressor/inotropes					
Not required		1391 (97.1)	71 (97.3)	81 (98.8)	1543 (97.2)
Use within 28 days	Total	18 (1.3)	2 (2.7)	1 (1.2)	21 (1.3)
	Prior to discharge	17 (1.2)	2 (2.7)	1 (1.2)	20 (1.3)
	Post-discharge	3 (0.2)	0 (0.0)	0 (0.0)	3 (0.2)
Unknown		24 (1.7)	0 (0.0)	0 (0.0)	24 (1.5)
Total		1433 (100.0)	73 (100.0)	82 (100.0)	1588 (100.0)
Ventilation					
Not required		1339 (93.4)	65 (89.0)	78 (95.1)	1482 (93.3)
Use within 28 days	Total	76 (5.3)	8 (11.0)	4 (4.9)	88 (5.5)
	Prior to discharge	58 (4.0)	8 (11.0)	4 (4.9)	70 (4.4)
	Post-discharge	18 (1.3)	0 (0.0)	0 (0.0)	18 (1.1)
Unknown		18 (1.3)	0 (0.0)	0 (0.0)	18 (1.1)
Total		1433 (100.0)	73 (100.0)	82 (100.0)	1588 (100.0)

Table 2.23: Breakdown of primary composite outcomes by treatment group and interim of enrolment.

	Domain A			Domain C				
Outcome	Not randomised A	SoC	Nafamostat	Not randomised C	Low	Intermediate	Low with aspirin	Therapeutic
Overall (n = 1588)								
Randomised	1433	73	82	32	610	613	283	50
Known	1410 (98)	73 (100)	82 (100)	32 (100)	598 (98)	606 (99)	279 (99)	50 (100)
Met primary outcome	79 (6)	8 (11)	4 (5)	4 (12)	35 (6)	25 (4)	20 (7)	7 (14)
Death	50 (4)	0 (0)	0 (0)	0 (0)	19 (3)	15 (2)	10 (4)	6 (12)
Vasopressor/inotropic support	18 (1)	2 (3)	1 (1)	1 (3)	6 (1)	6 (1)	6 (2)	2 (4)
Intensive respiratory support	76 (5)	8 (11)	4 (5)	4 (12)	35 (6)	24 (4)	18 (6)	7 (14)
Interim 1 (n = 685)								
Randomised	683	-	2	-	234	226	225	-
Known	669 (98)	-	2 (100)	-	227 (97)	222 (98)	222 (99)	-
Met primary outcome	56 (8)	-	0 (0)	-	22 (10)	15 (7)	19 (9)	-
Death	33 (5)	-	0 (0)	-	13 (6)	11 (5)	9 (4)	-
Vasopressor/inotropic support	11 (2)	-	0 (0)	-	2 (1)	3 (1)	6 (3)	-
Intensive respiratory support	54 (8)	-	0 (0)	-	22 (10)	15 (7)	17 (8)	-
Interim 2 (n = 259)								
Randomised	202	31	26	13	90	98	58	-
Known	201 (100)	31 (100)	26 (100)	13 (100)	90 (100)	98 (100)	57 (98)	-
Met primary outcome	6 (3)	0 (0)	0 (0)	0 (0)	2 (2)	3 (3)	1 (2)	-
Death	5 (2)	0 (0)	0 (0)	0 (0)	1 (1)	3 (3)	1 (2)	-
Vasopressor/inotropic support	1 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	-
Intensive respiratory support	6 (3)	0 (0)	0 (0)	0 (0)	2 (2)	3 (3)	1 (2)	-
Interim 3 (n = 392)								
Randomised	326	29	37	8	177	172	-	35
Known	323 (99)	29 (100)	37 (100)	8 (100)	175 (99)	171 (99)	-	35 (100)
Met primary outcome	12 (4)	7 (24)	2 (5)	3 (38)	8 (5)	4 (2)	-	6 (17)
Death	9 (3)	0 (0)	0 (0)	0 (0)	4 (2)	0 (0)	-	5 (14)
Vasopressor/inotropic support	5 (2)	2 (7)	0 (0)	0 (0)	3 (2)	2 (1)	-	2 (6)
Intensive respiratory support	12 (4)	7 (24)	2 (5)	3 (38)	8 (5)	4 (2)	-	6 (17)
Interim 4 (n = 237)								
Randomised	220	6	11	3	108	112	-	14
Known	216 (98)	6 (100)	11 (100)	3 (100)	105 (97)	111 (99)	-	14 (100)
Met primary outcome	5 (2)	1 (17)	2 (18)	1 (33)	3 (3)	3 (3)	-	1 (7)
Death	3 (1)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	-	1 (7)
Vasopressor/inotropic support	1 (0)	0 (0)	1 (9)	1 (33)	0 (0)	1 (1)	-	0 (0)
Intensive respiratory support	4 (2)	1 (17)	2 (18)	1 (33)	3 (3)	2 (2)	-	1 (7)
Interim 5 (n = 15)								
Randomised	2	7	6	8	1	5	-	1
Known	1 (50)	7 (100)	6 (100)	8 (100)	1 (100)	4 (80)	-	1 (100)
Met primary outcome	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	-	0 (0)
Death	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	-	0 (0)
Vasopressor/inotropic support	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	-	0 (0)
Intensive respiratory support	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	-	0 (0)

2.2.2 Primary Analysis

The primary model was a logistic regression model adjusting for anticoagulation treatment, antiviral treatment, age (≥ 60 or not), oxygen requirement (required supplemental oxygen or not), and region (India (ref), Australia/New Zealand, and Nepal), with random effects for site (nested within country) and epoch (calendar time 4 week intervals, most recent epoch as reference). The three most recent epochs were combined due to small numbers, and the two earliest epochs were combined for the same reason. Sites with fewer than 5 enrolments were combined within region into an "other sites" category. An odds ratio less than 1 implies a benefit (reduction in the odds of primary outcome).

2.2.2.1 FAS-ITT

The SAP specified that the analysis based on FAS-ITT as secondary. However, this analysis using all the available platform data is presented first.

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch
- **Set**: FAS-ITT

The trial decision quantities are reported in Table 2.24 and the model parameter posteriors are summarised in Table 2.25 and Figure 2.14.

Table 2.24: Summary of domain decision qauntities for primary outcome model fit to the FAS-ITT set.

Intervention	Posterior	Superior Pr(OR = min(OR))	Effective Pr(OR < 1)	Futile Pr(OR > 1/1.1)	Equivalent Pr(1/1.1 < OR < 1.1)
Antiviral					
SoC	1.00	0.05	-	-	-
Nafamostat	0.36 (0.10, 1.20)	0.95	0.95	0.07	0.03
Anticoagulation					
Low-dose	1.00	0.07	-	-	-
Intermediate-dose	0.71 (0.40, 1.22)	0.66	0.89	0.19	0.13
Low-dose with aspirin	0.85 (0.45, 1.59)	0.27	0.69	0.42	0.21
Therapeutic-dose	2.60 (0.93, 7.18)	0.01	0.04	0.98	0.03

Table 2.25: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the FAS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.36	(0.10, 1.20)	0.44 (0.30)	0.95
Intermediate-dose	0.71	(0.40, 1.22)	0.73 (0.21)	0.89
Low-dose with aspirin	0.85	(0.45, 1.59)	0.90 (0.29)	0.69
Therapeutic-dose	2.60	(0.93, 7.18)	2.97 (1.65)	0.04
Ineligible aspirin	2.30	(0.60, 7.50)	2.73 (1.82)	0.10
Age ≥ 60	1.73	(1.06, 2.82)	1.78 (0.45)	0.02
Female	0.64	(0.38, 1.04)	0.65 (0.17)	0.97
Oxygen requirement	3.66	(2.21, 6.20)	3.81 (1.03)	0.00
Australia/New Zealand	1.02	(0.25, 3.93)	1.30 (1.02)	0.49
Nepal	1.58	(0.41, 5.50)	1.95 (1.44)	0.24

Figure 2.13: Posterior densities for the treatment effect odds ratios, FAS-ITT.

Figure 2.14: Posterior Summaries (point - median, block - 75% CrI, line 0.95% CrI) of odds
ratio for epoch and site effects for the primary outcome model fit to the FAS-ITT
set.

2.2.2.2 AVS-ITT

The SAP pre-specified that the primary model would be fit using the AVS-ITT including all the pre-specified covariates. This analysis deviated from that specified in the SAP for a number of reasons:

- almost all in AVS-ITT were enrolled in Australia/New Zealand, with no events observed in Nepal, so region was dropped from the model
- there was concurrent randomisation to antiviral domain (where available) throughout the entire study, so epoch term dropped was dropped from the model
- other covariates dropped due to small number of cases and events (ineligible for aspirin, site).

Therefore, the analysis restricted to the AVS-ITT set was based on a reduced model compared to that specified in the SAP. Due to the small number of events, the parameter posteriors will be sensitive to the priors.

In summary, the analysis was based on the following:

- **Model**: logistic regression
- **Terms**: antiviral intervention, anticoagulation intervention, age group, sex, oxygen requirement, CRP tertiles
- **Set**: AVS-ITT

Table 2.26: Summary of domain decision qauntities for primary outcome model fit to the AVS-ITT set.

Intervention	Posterior	Superior $\Pr(OR = \min(OR))$	Effective $\Pr(OR < 1)$	Futile $\Pr(OR > 1/1.1)$	Equivalent $\Pr(1/1.1 < OR < 1.1)$
Antiviral					
SoC	1.00	0.07	-	-	-
Nafamostat	0.40 (0.12, 1.34)	0.93	0.93	0.09	0.04

Table 2.27: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the AVS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.40	(0.12, 1.34)	0.48 (0.32)	0.93
Intermediate-dose	0.61	(0.14, 2.51)	0.79 (0.64)	0.76
Low-dose with aspirin	0.52	(0.07, 3.44)	0.83 (0.98)	0.75
Therapeutic-dose	0.83	(0.13, 4.60)	1.22 (1.26)	0.58
Age ≥ 60	1.21	(0.30, 4.44)	1.51 (1.14)	0.39
Female	0.65	(0.16, 2.30)	0.79 (0.58)	0.75
Required oxygen	2.67	(0.59, 16.97)	4.16 (5.52)	0.11
CRP (2nd tertile)	3.15	(0.74, 15.08)	4.36 (4.25)	0.06
CRP (3rd tertile)	0.85	(0.14, 4.75)	1.25 (1.39)	0.58
CRP (unknown)	0.18	(0.00, 2.77)	0.48 (1.11)	0.88

Figure 2.15: Posterior densities for the treatment effect odds ratios, AVS-ITT.

2.2.2.3 ACS-ITT

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch
- **Set**: ACS-ITT

Table 2.28: Summary of domain decision qauntities (relative to standard dose) for primary outcome model fit to the ACS-ITT set.

Intervention	Posterior	Superior Pr(OR = min(OR))	Effective Pr(OR < 1)	Futile Pr(OR > 1/1.1)	Equivalent Pr(1/1.1 < OR < 1.1)
Antiviral					
SoC	1.00	0.03	-	-	-
Nafamostat	0.24 (0.05, 1.02)	0.97	0.97	0.04	0.02
Anticoagulation					
Low-dose	1.00	0.06	-	-	-
Intermediate-dose	0.70 (0.39, 1.22)	0.67	0.90	0.18	0.12
Low-dose with aspirin	0.85 (0.45, 1.57)	0.27	0.69	0.42	0.21
Therapeutic-dose	2.57 (0.88, 7.20)	0.01	0.04	0.97	0.03

Table 2.29: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.24	(0.05, 1.02)	0.31 (0.27)	0.97
Intermediate-dose	0.70	(0.39, 1.22)	0.73 (0.21)	0.90
Low-dose with aspirin	0.85	(0.45, 1.57)	0.89 (0.29)	0.69
Therapeutic-dose	2.57	(0.88, 7.20)	2.95 (1.68)	0.04
Ineligible aspirin	2.55	(0.66, 8.59)	3.08 (2.12)	0.08
Age $\geq$ 60	1.76	(1.06, 2.95)	1.82 (0.48)	0.02
Female	0.64	(0.38, 1.05)	0.66 (0.17)	0.96
Oxygen requirement	3.77	(2.25, 6.45)	3.92 (1.08)	0.00
Australia/New Zealand	0.83	(0.18, 3.44)	1.08 (0.90)	0.60
Nepal	1.74	(0.44, 6.19)	2.14 (1.61)	0.21

Figure 2.16: Posterior densities for the treatment effect odds ratios, ACS-ITT.

Figure 2.17: Posterior Summaries (point - median, block - 75% CrI, line 0.95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the ACS-ITT set.

2.2.2.4 FAS-PP

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch
- **Set**: FAS-PP

Table 2.30: Summary of primary composite outcome by anticoagulation treatment group, FAS-PP.

n (%)	Not randomised to anticoagulation	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	26	595	596	274	44	1535
Outcome missing	0 (0.0)	12 (2.0)	7 (1.2)	3 (1.1)	0 (0.0)	22 (1.4)
Outcome observed	26 (100.0)	583 (98.0)	589 (98.8)	271 (98.9)	44 (100.0)	1513 (98.6)
Met primary outcome	2 (7.7)	35 (6.0)	25 (4.2)	19 (7.0)	6 (13.6)	87 (5.8)

Table 2.31: Summary of primary composite outcome by antiviral treatment group, FAS-PP.

n (%)	Not randomised to antiviral	Standard of care	Nafamostat	Overall
Randomised	1409	67	59	1535
Outcome missing	22 (1.6)	0 (0.0)	0 (0.0)	22 (1.4)
Outcome observed	1387 (98.4)	67 (100.0)	59 (100.0)	1513 (98.6)
Met primary outcome	78 (5.6)	8 (11.9)	1 (1.7)	87 (5.8)

Table 2.32: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the FAS-PP set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.15	(0.03, 0.64)	0.19 (0.17)	1.00
Intermediate-dose	0.71	(0.41, 1.21)	0.73 (0.21)	0.89
Low-dose with aspirin	0.81	(0.42, 1.52)	0.85 (0.28)	0.75
Therapeutic-dose	2.55	(0.81, 7.58)	2.97 (1.78)	0.05
Ineligible aspirin	2.29	(0.61, 7.50)	2.74 (1.87)	0.10
Age ≥ 60	1.72	(1.04, 2.82)	1.77 (0.46)	0.02
Female	0.57	(0.34, 0.93)	0.59 (0.15)	0.99
Oxygen requirement	3.86	(2.32, 6.50)	3.99 (1.08)	0.00
Australia/New Zealand	0.94	(0.21, 3.91)	1.22 (1.00)	0.53
Nepal	1.63	(0.40, 6.01)	2.02 (1.51)	0.23

Figure 2.18: Posterior densities for the treatment effect odds ratios, FAS-PP

2.2.2.5 AVS-PP

- **Model**: logistic regression
- **Terms**: antiviral intervention, anticoagulation intervention, age group, sex, oxygen requirement
- **Set**: AVS-PP

Table 2.33: Summary of primary composite outcome by anticoagulation treatment group, AVS-PP.

n (%)	Not randomised to anticoagulation	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	28	43	44	7	13	135
Outcome missing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Outcome observed	28 (100.0)	43 (100.0)	44 (100.0)	7 (100.0)	13 (100.0)	135 (100.0)
Met primary outcome	2 (7.1)	4 (9.3)	3 (6.8)	0 (0.0)	0 (0.0)	9 (6.7)

Table 2.34: Summary of primary composite outcome by antiviral treatment group, AVS-PP.

n (%)	Standard of care	Nafamostat	Overall
Randomised	72	63	135
Outcome missing	0 (0.0)	0 (0.0)	0 (0.0)
Outcome observed	72 (100.0)	63 (100.0)	135 (100.0)
Met primary outcome	8 (11.1)	1 (1.6)	9 (6.7)

Table 2.35: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the AVS-PP set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.15	(0.03, 0.64)	0.19 (0.17)	1.00
Intermediate-dose	0.85	(0.15, 4.66)	1.25 (1.36)	0.57
Low-dose with aspirin	0.60	(0.07, 5.40)	1.14 (1.81)	0.67
Therapeutic-dose	0.52	(0.06, 4.01)	0.90 (1.24)	0.73
Age $\geq$ 60	0.98	(0.16, 4.97)	1.38 (1.43)	0.51
Female	0.22	(0.03, 1.23)	0.33 (0.34)	0.96
Required oxygen	7.27	(1.03, 79.13)	15.25 (30.06)	0.02
CRP (2nd tertile)	1.20	(0.17, 7.77)	1.88 (2.28)	0.43
CRP (3rd tertile)	0.84	(0.12, 5.50)	1.32 (1.63)	0.58
CRP (unknown)	0.21	(0.00, 4.90)	0.75 (1.95)	0.82
Nepal	0.81	(0.12, 5.24)	1.27 (1.50)	0.59

Figure 2.19: Posterior densities for the treatment effect odds ratios, AVS-PP

2.2.2.6 ACS-PP

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch
- **Set**: ACS-PP

Table 2.36: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the ACS-PP set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.20	(0.04, 0.90)	0.27 (0.24)	0.98
Intermediate-dose	0.69	(0.39, 1.20)	0.72 (0.21)	0.91
Low-dose with aspirin	0.82	(0.43, 1.54)	0.86 (0.29)	0.73
Therapeutic-dose	3.01	(0.99, 8.74)	3.48 (2.08)	0.03
Ineligible aspirin	2.53	(0.65, 8.55)	3.04 (2.15)	0.09
Age ≥ 60	1.74	(1.06, 2.88)	1.81 (0.47)	0.02
Female	0.61	(0.36, 1.00)	0.63 (0.16)	0.98
Oxygen requirement	3.80	(2.26, 6.52)	3.94 (1.09)	0.00
Australia/New Zealand	0.87	(0.20, 3.64)	1.14 (0.94)	0.57
Nepal	1.63	(0.41, 5.88)	2.03 (1.51)	0.23

Figure 2.20: Posterior densities for the treatment effect odds ratios, ACS-PP

2.2.2.7 FAS-ITT Antiviral/Anticoagulation Interaction

The SAP specified investigation of interaction effects between Nafamostat and the anticoagulation domain. The number of events within cells were very small, so the results are uninformative.

Table 2.37: Summary of participant outcomes by assigned anticoagulation intervention in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Not randomised to anticoagulation			
Not randomised to antiviral	0	0	- (-%)
Standard of care	18	18	2 (11%)
Nafamostat	14	14	2 (14%)
Low-dose anticoagulation			
Not randomised to antiviral	562	550	31 (6%)
Standard of care	26	26	3 (12%)
Nafamostat	22	22	1 (5%)
Intermediate-dose anticoagulation			
Not randomised to antiviral	560	553	22 (4%)
Standard of care	19	19	3 (16%)
Nafamostat	34	34	0 (0%)
Low-dose anticoagulation with aspirin			
Not randomised to antiviral	276	272	20 (7%)
Standard of care	6	6	0 (0%)
Nafamostat	1	1	0 (0%)
Therapeutic-dose anticoagulation			
Not randomised to antiviral	35	35	6 (17%)
Standard of care	4	4	0 (0%)
Nafamostat	11	11	1 (9%)

Table 2.38: Summary of odds ratios for treatment effects by assigned anticoagulation intervention in the FAS-ITT set.

Anticoagulation	Median	95% CrI	Mean (SD)	$Pr(OR < 1)$	$Pr(OR > 1/1.1)$
Nafamostat					
Low	0.28	(0.04, 1.89)	0.45 (0.56)	0.90	0.11
Intermediate	0.15	(0.01, 1.17)	0.26 (0.34)	0.97	0.04
Low with aspirin	0.72	(0.04, 14.28)	2.22 (5.78)	0.59	0.44
Therapeutic	0.71	(0.05, 10.58)	1.75 (3.66)	0.59	0.43

Table 2.39: Summary of odds ratio comparisons of treatment effects by by assigned anticoagulation intervention in the FAS-ITT set.

Anticoagulation	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Low	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Intermediate	0.53	(0.03, 7.86)	1.37 (2.93)	0.67
Low with aspirin	2.56	(0.10, 69.56)	10.86 (41.71)	0.29
Therapeutic	2.59	(0.13, 56.27)	9.51 (48.45)	0.28

Figure 2.21: Posterior densities of odds ratio for antiviral interventions relative to standard dose by by assigned anticoagulation intervention using FAS-ITT set.

Figure 2.22: Posterior predictive distribution of primary outcome proportion for antiviral interventions by by assigned anticoagulation intervention using FAS-ITT set. Red diamonds indicate sample proportions.

2.2.3 Sensitivity Analyses

The SAP outlined a number of sensitivity analyses. Any sensitivity analyses not outlined in the SAP will be indicated as post-hoc.

2.2.3.1 AVS-ITT Treatment Only (Post-hoc)

The SAP pre-specified a number of covariates for the analysis based on the AVS-ITT. These were included, but due to the small number of events there may be little data to inform the model parameters. Therefore, the AVS-ITT analyses was also undertaken where the model only contained a term for the antiviral intervention received. The results of this treatment-only model are reported below.

Table 2.40: Summary of model parameters (fixed-effects odds-ratios) for treatment-only model fit to the AVS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.48	(0.15, 1.42)	0.56 (0.34)	0.91

Figure 2.23: Posterior densities for the treatment effect odds ratios, AVS-ITT.

2.2.3.2 FAS-ITT "Best-case" scenario

Table 2.41: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the FAS-ITT set assuming missing do not meet primary outcome.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.35	(0.10, 1.23)	0.43 (0.30)	0.95
Intermediate-dose	0.71	(0.41, 1.24)	0.74 (0.21)	0.89
Low-dose with aspirin	0.86	(0.46, 1.59)	0.90 (0.29)	0.69
Therapeutic-dose	2.68	(0.94, 7.35)	3.06 (1.71)	0.03
Ineligible aspirin	2.56	(0.70, 8.18)	3.04 (2.00)	0.08
Age ≥ 60	1.73	(1.06, 2.83)	1.78 (0.45)	0.01
Female	0.64	(0.38, 1.03)	0.66 (0.17)	0.97
Oxygen requirement	3.67	(2.21, 6.18)	3.82 (1.02)	0.00
Australia/New Zealand	0.97	(0.24, 3.74)	1.22 (0.95)	0.52
Nepal	1.59	(0.40, 5.74)	1.96 (1.45)	0.25

Figure 2.24: Posterior densities for the treatment effect odds ratios, FAS-ITT set assuming missing do not meet primary outcome.

Figure 2.25: Posterior Summaries (point - median, block - 75% CrI, line 0.95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the FAS-ITT set assuming missing do not meet primary outcome.

2.2.3.3 FAS-ITT "Worst-case" scenario

Table 2.42: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the FAS-ITT set assuming missing meet primary outcome.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.39	(0.11, 1.30)	0.47 (0.32)	0.94
Intermediate-dose	0.67	(0.40, 1.09)	0.69 (0.18)	0.94
Low-dose with aspirin	0.76	(0.43, 1.34)	0.79 (0.23)	0.84
Therapeutic-dose	1.75	(0.63, 4.59)	1.97 (1.03)	0.14
Ineligible aspirin	1.13	(0.31, 3.56)	1.34 (0.86)	0.42
Age $\geq$ 60	1.61	(1.04, 2.48)	1.65 (0.37)	0.02
Female	0.79	(0.51, 1.22)	0.81 (0.18)	0.86
Oxygen requirement	2.87	(1.82, 4.57)	2.95 (0.70)	0.00
Australia/New Zealand	2.01	(0.51, 7.40)	2.51 (1.86)	0.16
Nepal	1.47	(0.36, 5.27)	1.81 (1.35)	0.29

Figure 2.26: Posterior densities for the treatment effect odds ratios, FAS-ITT set assuming missing meet primary outcome.

Figure 2.27: Posterior Summaries (point - median, block - 75% CrI, line 0.95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the FAS-ITT set assuming missing meet primary outcome.

2.2.3.4 FAS-ITT Australia/New Zealand Only

Table 2.43: Summary of model parameters (fixed-effects odds-ratios) for primary outcome model fit to the FAS-ITT set restricted to Australia/New Zealand.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.39	(0.10, 1.36)	0.47 (0.33)	0.93
Intermediate-dose	1.01	(0.25, 4.08)	1.30 (1.10)	0.50
Low-dose with aspirin	1.04	(0.11, 8.59)	1.87 (2.83)	0.49
Therapeutic-dose	1.10	(0.17, 6.43)	1.65 (1.83)	0.46
Age $\geq$ 60	1.30	(0.29, 5.21)	1.67 (1.36)	0.36
Female	0.66	(0.16, 2.44)	0.82 (0.62)	0.73
Oxygen requirement	1.88	(0.42, 10.04)	2.72 (3.26)	0.20

Figure 2.28: Posterior densities for the treatment effect odds ratios, FAS-ITT set restricted to Australia/New Zealand.

Figure 2.29: Posterior Summaries (point - median, block - 75% CrI, line 0.95% CrI) of odds ratio for epoch and site effects for the primary outcome model fit to the FAS-ITT set restricted to Australia/New Zealand.

2.2.3.5 Concurrent Randomisations

The SAP requested an analysis of primary and secondary outcomes restricted to concurrent randomisations. For the antiviral domain, both interventions were concurrently randomised 1:1 throughout the platform. Therefore, this restriction is equivalent to the restriction to the AVS-ITT analyses which are reported for all outcomes.

Analyses of the anticoagulation domain restricted to concurrent randomisations were reported in the anticoagulation domain report.

2.2.4 Subgroups

The pre-specified subgroups where treatment effect heterogeneity with respect to Nafamostat was to be investigated were:

- region (India, Australia/New Zealand, Nepal)
- days since symptom onset (≤ 7 or > 7 days)
- age at enrolment (< 60 or ≥ 60 years of age)
- supplemental oxygen or oxygen saturation less than 94% at randomisation (yes or no)
- receipt of corticosteroid during hospital stay (yes or no)
- receipt of remdesivir during hospital stay (yes or no)
- receipt of other agent intended to be antiviral against SARS-CoV-2 during hospital stay (yes or no)
- vaccination status

Domain-specific subgroups were additionally specified as:

- presence of iatrogenic immunosuppression at randomisation
- D-dimer above upper limit of normal at baseline (yes or no)

The analysts note that:

- The antiviral domain was almost exclusive to participants in Australia/New Zealand (5 were randomised in Nepal, 0 in India), therefore, no subgroup analysis was undertaken for region
- Given the small number of events in the antiviral domain, there is little data to inform subgroup specific effects for Nafamostat beyond what is assumed in the specified prior.
- Some of the subgroups relate to post-randomisation events, which make interpretation of the treatment effects difficult.

For each sub-group analysis, the primary model was extended to include an interaction term between the covariate of interest and the antiviral interventions (not randomised and randomised to Nafamostat).

Variable	SoC	Nafamostat	Odds ratio (median, 95% CrI)	
	events/patients (proportion)			
Age				
< 60 yr	5/54 (0.09)	3/60 (0.05)		0.37 (0.09, 1.42)
≥ 60 yr	3/19 (0.16)	1/22 (0.05)		0.30 (0.04, 2.20)
Days since first symptoms				
≤ 7	6/34 (0.18)	2/42 (0.05)		0.29 (0.07, 1.15)
> 7	2/39 (0.05)	2/40 (0.05)		0.54 (0.08, 3.27)
Supplemental oxygen				
Room air and SpO2 ≥ 94%	0/23 (0.00)	1/19 (0.05)		0.76 (0.12, 4.81)
Not room air or SpO2 < 94% on RA	8/50 (0.16)	3/63 (0.05)		0.25 (0.06, 1.02)
Corticosteroids				
Did not receive corticosteroids	0/18 (0.00)	1/12 (0.08)		0.94 (0.14, 5.89)
Received corticosteroids	8/55 (0.15)	3/70 (0.04)		0.22 (0.05, 0.89)
Remdesivir				
Did not receive remdesivir	5/34 (0.15)	2/43 (0.05)		0.33 (0.07, 1.42)
Received remdesivir	3/39 (0.08)	2/39 (0.05)		0.32 (0.05, 1.79)
Other antiviral				
Did not receive other antivirals	6/66 (0.09)	3/72 (0.04)		0.37 (0.10, 1.29)
Received other antivirals	2/7 (0.29)	1/10 (0.10)		0.30 (0.03, 2.83)
Vaccination				
Not vaccinated	7/39 (0.18)	2/50 (0.04)		0.27 (0.07, 1.01)
Vaccinated	1/27 (0.04)	2/31 (0.06)		0.91 (0.10, 7.13)
D-dimer				
No	1/19 (0.05)	1/18 (0.06)		0.45 (0.09, 2.26)
Yes	4/35 (0.11)	2/32 (0.06)		0.37 (0.06, 2.03)
Unknown	3/19 (0.16)	1/32 (0.03)		0.21 (0.02, 1.50)
Randomisation date				
< 2021-12-20	8/63 (0.13)	2/68 (0.03)		0.30 (0.08, 1.01)
≥ 2021-12-20	0/10 (0.00)	2/14 (0.14)		1.77 (0.16, 19.07)
Country				
Australia	4/65 (0.06)	3/67 (0.04)		0.77 (0.18, 3.29)
Nepal	0/2 (0.00)	0/3 (0.00)		1.03 (0.08, 12.96)
New Zealand	4/6 (0.67)	1/12 (0.08)		0.13 (0.02, 0.81)

0.1   0.25 0.5   1   2   4   10

← Nafamostat better   SoC better →

Figure 2.30: Posterior odds ratio summaries for subgroups, FAS-ITT.

2.2.4.1 Region

A summary of the primary outcome by country and intervention is reported in Table 2.44 and Table 2.45. Note that no participants enrolled in Nepal or New Zealand received standard dose plus aspirin due to the timing of its removal from the domain. Additionally, no participants enrolled in India were randomised to the antiviral domain and very few in Nepal. No subgroup analysis for Nafamostat was undertaken for region as there were no events observed in the antiviral domain outside of Australia/New Zealand.

Table 2.44: Summary of participant outcomes by region of enrolment in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
India			
Not randomised to anticoagulation	0	0	- (-%)
Low dose	493	486	27 (6%)
Intermediate dose	516	511	20 (4%)
Low dose with aspirin	275	272	20 (7%)
Therapeutic dose	4	4	0 (0%)
Australia/New Zealand			
Not randomised to anticoagulation	27	27	4 (15%)
Low dose	61	59	4 (7%)
Intermediate dose	66	64	4 (6%)
Low dose with aspirin	8	7	0 (0%)
Therapeutic dose	15	15	1 (7%)
Nepal			
Not randomised to anticoagulation	5	5	0 (0%)
Low dose	56	53	4 (8%)
Intermediate dose	31	31	1 (3%)
Low dose with aspirin	0	0	- (-%)
Therapeutic dose	31	31	6 (19%)

Table 2.45: Summary of participant outcomes by region of enrolment in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
India			
Not randomised to antiviral	1288	1273	67 (5%)
Standard of care	0	0	- (-%)
Nafamostat	0	0	- (-%)
Australia/New Zealand			
Not randomised to antiviral	27	22	1 (5%)
Standard of care	71	71	8 (11%)
Nafamostat	79	79	4 (5%)
Nepal			
Not randomised to antiviral	118	115	11 (10%)
Standard of care	2	2	0 (0%)
Nafamostat	3	3	0 (0%)

2.2.4.2 Country (Exploratory)

As an exploratory analysis, the region subgroup analysis was reported by individual country (rather than with Australia and New Zealand combined).

Table 2.46: Summary of participant outcomes by country of enrolment in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
India			
Not randomised to anticoagulation	0	0	- (-%)
Low dose	493	486	27 (6%)
Intermediate dose	516	511	20 (4%)
Low dose with aspirin	275	272	20 (7%)
Therapeutic dose	4	4	0 (0%)
Australia			
Not randomised to anticoagulation	24	24	2 (8%)
Low dose	49	49	2 (4%)
Intermediate dose	59	58	3 (5%)
Low dose with aspirin	7	7	0 (0%)
Therapeutic dose	11	11	1 (9%)
Nepal			
Not randomised to anticoagulation	5	5	0 (0%)
Low dose	56	53	4 (8%)
Intermediate dose	31	31	1 (3%)
Low dose with aspirin	0	0	- (-%)
Therapeutic dose	31	31	6 (19%)
New Zealand			
Not randomised to anticoagulation	3	3	2 (67%)
Low dose	12	10	2 (20%)
Intermediate dose	7	6	1 (17%)
Low dose with aspirin	1	0	- (-%)
Therapeutic dose	4	4	0 (0%)

Table 2.47: Summary of participant outcomes by country of enrolment in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
India			
Not randomised to antiviral	1288	1273	67 (5%)
Standard of care	0	0	- (-%)
Nafamostat	0	0	- (-%)
Australia			
Not randomised to antiviral	18	17	1 (6%)
Standard of care	65	65	4 (6%)
Nafamostat	67	67	3 (4%)
Nepal			
Not randomised to antiviral	118	115	11 (10%)
Standard of care	2	2	0 (0%)
Nafamostat	3	3	0 (0%)
New Zealand			
Not randomised to antiviral	9	5	0 (0%)
Standard of care	6	6	4 (67%)
Nafamostat	12	12	1 (8%)

Table 2.48: Summary of odds ratios for treatment effects by country of enrolment in the FAS-ITT set.

Country	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Australia	0.77	(0.18, 3.29)	1.01 (0.86)	0.64	0.41
Nepal	1.03	(0.08, 12.96)	2.41 (5.61)	0.49	0.54
New Zealand	0.13	(0.02, 0.81)	0.20 (0.24)	0.99	0.02

Table 2.49: Summary of odds ratio comparisons of treatment effects by country of enrolment in the FAS-ITT set.

Country	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Australia	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Nepal	1.34	(0.07, 24.20)	4.08 (12.64)	0.43
New Zealand	0.16	(0.01, 1.81)	0.35 (0.64)	0.93

Figure 2.31: Posterior densities of odds ratio for antiviral interventions relative to standard dose by country of enrolment subgroup using FAS-ITT set.

Figure 2.32: Posterior predictive distribution of primary outcome proportion for antiviral interventions by country of enrolment subgroup using FAS-ITT set. Red diamonds indicate sample proportions.

2.2.4.3 Age group

A subgroup analysis of age group (< 60 or ≥ 60 years of age) was undertaken using the FAS-ITT set. A summary of the primary outcome by age group and intervention is reported in Table 2.50.

Table 2.50: Summary of participant outcomes by age group at enrolment in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Age < 60 years			
Not randomised to anticoagulation	25	25	3 (12%)
Low dose	445	438	18 (4%)
Intermediate dose	436	431	15 (3%)
Low dose with aspirin	195	192	11 (6%)
Therapeutic dose	26	26	3 (12%)
Age ≥ 60 years			
Not randomised to anticoagulation	7	7	1 (14%)
Low dose	165	160	17 (11%)
Intermediate dose	177	175	10 (6%)
Low dose with aspirin	88	87	9 (10%)
Therapeutic dose	24	24	4 (17%)

Table 2.51: Summary of participant outcomes by age group at enrolment in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Age < 60 years			
Not randomised to antiviral	1013	998	42 (4%)
Standard of care	54	54	5 (9%)
Nafamostat	60	60	3 (5%)
Age ≥ 60 years			
Not randomised to antiviral	420	412	37 (9%)
Standard of care	19	19	3 (16%)
Nafamostat	22	22	1 (5%)

Table 2.52: Summary of odds ratios for treatment effects by age of enrolment in the FAS-ITT set.

Age	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Age < 60	0.37	(0.09, 1.42)	0.47 (0.36)	0.92	0.10
Age ≥ 60	0.30	(0.04, 2.20)	0.50 (0.63)	0.88	0.14

Table 2.53: Summary of odds ratio comparisons of treatment effects by age of enrolment in the FAS-ITT set.

Age	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Age < 60	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Age ≥ 60	0.80	(0.11, 6.26)	1.35 (1.84)	0.59

Figure 2.33: Posterior densities of odds ratio for antiviral interventions relative to standard dose by age subgroup using FAS-ITT set.

Figure 2.34: Posterior predictive distribution of primary outcome proportion for antiviral interventions by age subgroup using FAS-ITT set. Red diamonds indicate sample proportions.

2.2.4.4 Days since symptom onset

A subgroup analysis of days since first symptoms (DSFS) group (≤ 7 or > 7 days) was undertaken using the FAS-ITT set. A summary of the primary outcome by DSFS group and intervention is reported in Table 2.54.

Table 2.54: Summary of participant outcomes by days since symptom onset in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Days since first symptoms ≤ 7			
Not randomised to anticoagulation	17	17	3 (18%)
Low dose	421	414	22 (5%)
Intermediate dose	432	429	20 (5%)
Low dose with aspirin	206	203	15 (7%)
Therapeutic dose	39	39	5 (13%)
Days since first symptoms > 7			
Not randomised to anticoagulation	15	15	1 (7%)
Low dose	189	184	13 (7%)
Intermediate dose	181	177	5 (3%)
Low dose with aspirin	77	76	5 (7%)
Therapeutic dose	11	11	2 (18%)

Table 2.55: Summary of participant outcomes by days since symptom onset in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Days since first symptoms ≤ 7			
Not randomised to antiviral	1039	1026	57 (6%)
Standard of care	34	34	6 (18%)
Nafamostat	42	42	2 (5%)
Days since first symptoms > 7			
Not randomised to antiviral	394	384	22 (6%)
Standard of care	39	39	2 (5%)
Nafamostat	40	40	2 (5%)

Table 2.56: Summary of odds ratios for treatment effects by DSFS of enrolment in the FAS-ITT set.

Days since symptom onset	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Days from symptom onset ≤ 7	0.29	(0.07, 1.15)	0.37 (0.30)	0.96	0.05
Days from symptom onset > 7	0.54	(0.08, 3.27)	0.82 (0.98)	0.75	0.28

Table 2.57: Summary of odds ratio comparisons of treatment effects by DSFS of enrolment in the FAS-ITT set.

Days since symptom onset	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Days from symptom onset ≤ 7	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Days from symptom onset > 7	1.83	(0.27, 12.27)	2.94 (3.72)	0.27

Figure 2.35: Posterior densities of odds ratio for antiviral interventions relative to standard dose by days since first symptoms subgroup using FAS-ITT set.

Figure 2.36: Posterior predictive distribution of primary outcome proportion for antiviral interventions by days since first symptoms subgroup using FAS-ITT set. Red diamonds indicate sample proportions.

2.2.4.5 Oxygen requirement

A subgroup analysis for supplemental oxygen requirement at baseline was undertaken using the FAS-ITT set.

Table 2.58: Summary of participant outcomes by room air and oxygen saturation in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Did not required supplemental oxygen			
Not randomised to anticoagulation	9	9	1 (11%)
Low dose	358	349	11 (3%)
Intermediate dose	372	369	11 (3%)
Low dose with aspirin	179	177	7 (4%)
Therapeutic dose	24	24	1 (4%)
Required supplemental oxygen			
Not randomised to anticoagulation	23	23	3 (13%)
Low dose	252	249	24 (10%)
Intermediate dose	241	237	14 (6%)
Low dose with aspirin	104	102	13 (13%)
Therapeutic dose	26	26	6 (23%)

Table 2.59: Summary of participant outcomes by room air and oxygen saturation in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Did not required supplemental oxygen			
Not randomised to antiviral	900	886	30 (3%)
Standard of care	23	23	0 (0%)
Nafamostat	19	19	1 (5%)
Required supplemental oxygen			
Not randomised to antiviral	533	524	49 (9%)
Standard of care	50	50	8 (16%)
Nafamostat	63	63	3 (5%)

Table 2.60: Summary of odds ratios for treatment effects by room air and oxygen saturation at enrolment in the FAS-ITT set.

Supplemental oxygen	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Did not require supplemental oxygen	0.76	(0.12, 4.81)	1.19 (1.40)	0.61	0.43
Required supplemental oxygen	0.25	(0.06, 1.02)	0.32 (0.26)	0.97	0.04

Table 2.61: Summary of odds ratio comparisons of treatment effects by room air and oxygen saturation at enrolment the FAS-ITT set.

Supplemental oxygen	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Did not require supplemental oxygen	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Required supplemental oxygen	0.32	(0.05, 2.26)	0.53 (0.65)	0.87

Figure 2.37: Posterior densities of odds ratio for antiviral interventions relative to standard dose by supplemental oxygen subgroup using FAS-ITT set.

Figure 2.38: Posterior predictive distribution of primary outcome proportion for antiviral interventions by supplemental oxygen subgroup using FAS-ITT set. Red diamonds indicate sample proportions, black points posterior-predictive medians.

2.2.4.6 Receipt of Corticosteroids

A summary of the primary outcome by receipt of corticosteroids and intervention is reported in Table 2.62 and Table 2.63.

It is noted that this subgroup analysis was pre-specified, however receipt of corticosteroids is reported on the discharge summary and is a post-randomisation event (any receipt during their index hospital admission). Therefore, interpretation of this subgroup is challenging (more severe patients may have been more likely to receive corticosteroids, availability may be site specific, etc.).

Table 2.62: Summary of participant outcomes by receipt of corticosteroids during index hospital stay in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Did not receive corticosteroids			
Not randomised to anticoagulation	12	12	0 (0%)
Low dose	214	210	8 (4%)
Intermediate dose	225	223	6 (3%)
Low dose with aspirin	100	98	4 (4%)
Therapeutic dose	13	13	1 (8%)
Received corticosteroids			
Not randomised to anticoagulation	20	20	4 (20%)
Low dose	396	388	27 (7%)
Intermediate dose	388	383	19 (5%)
Low dose with aspirin	183	181	16 (9%)
Therapeutic dose	37	37	6 (16%)

Table 2.63: Summary of participant outcomes by receipt of corticosteroids during index hospital stay in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Did not receive corticosteroids			
Not randomised to antiviral	534	526	18 (3%)
Standard of care	18	18	0 (0%)
Nafamostat	12	12	1 (8%)
Received corticosteroids			
Not randomised to antiviral	899	884	61 (7%)
Standard of care	55	55	8 (15%)
Nafamostat	70	70	3 (4%)

Table 2.64: Summary of odds ratios for treatment effects by receipt of corticosteroids in the
FAS-ITT set.

Received corticosteroids	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Did not receive corticosteroids	0.94	(0.14, 5.89)	1.47 (1.90)	0.53	0.51
Received corticosteroids	0.22	(0.05, 0.89)	0.29 (0.23)	0.98	0.02

Table 2.65: Summary of odds ratio comparisons of treatment effects by receipt of corticos-
teroids in the FAS-ITT set.

Received corticosteroids	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Did not receive corticosteroids	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received corticosteroids	0.24	(0.03, 1.64)	0.39 (0.50)	0.93

Figure 2.39: Posterior densities of odds ratio for antiviral interventions relative to standard
dose by receipt of steroids subgroup using FAS-ITT set.

Figure 2.40: Posterior predictive distribution of primary outcome proportion for antiviral interventions by receipt of steroids subgroup using FAS-ITT set. Red diamonds indicate sample proportions, black points posterior-predictive medians.

2.2.4.7 Receipt of Remdesivir

A summary of the primary outcome by receipt of remdesivir and intervention is reported in Table 2.66 and Table 2.67.

Table 2.66: Summary of participant outcomes by receipt of remdesivir during index hospital stay in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Did not receive remdesivir			
Not randomised to anticoagulation	24	24	3 (12%)
Low dose	324	315	7 (2%)
Intermediate dose	324	319	6 (2%)
Low dose with aspirin	114	112	2 (2%)
Therapeutic dose	40	40	5 (12%)
Received remdesivir			
Not randomised to anticoagulation	8	8	1 (12%)
Low dose	286	283	28 (10%)
Intermediate dose	289	287	19 (7%)
Low dose with aspirin	169	167	18 (11%)
Therapeutic dose	10	10	2 (20%)

Table 2.67: Summary of participant outcomes by receipt of remdesivir during index hospital stay in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Did not receive remdesivir			
Not randomised to antiviral	749	733	16 (2%)
Standard of care	34	34	5 (15%)
Nafamostat	43	43	2 (5%)
Received remdesivir			
Not randomised to antiviral	684	677	63 (9%)
Standard of care	39	39	3 (8%)
Nafamostat	39	39	2 (5%)

Table 2.68: Summary of odds ratios for treatment effects by receipt of remdesivir in the FAS-ITT set.

Received remdesivir	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Did not receive remdesivir	0.33	(0.07, 1.42)	0.43 (0.37)	0.93	0.08
Received remdesivir	0.32	(0.05, 1.79)	0.48 (0.53)	0.90	0.12

Table 2.69: Summary of odds ratio comparisons of treatment effects by receipt of remdesivir in the FAS-ITT set.

| Received remdesivir	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Did not receive remdesivir	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received remdesivir	0.99	(0.14, 6.65)	1.59 (2.08)	0.50

Figure 2.41: Posterior densities of odds ratio for antiviral interventions relative to standard dose by receipt of remdesivir subgroup using FAS-ITT set.

Figure 2.42: Posterior predictive distribution of primary outcome proportion for antiviral interventions by receipt of remdesivir subgroup using FAS-ITT set. Red diamonds indicate sample proportions, black points posterior-predictive medians.

2.2.4.8 Receipt of other antiviral agent

A summary of the primary outcome by receipt of other antiviral and intervention is reported in Table 2.70 and Table 2.71.

This subgroup analysis was pre-specified, however receipt of an antiviral is reported on the discharge summary and is a post-randomisation event.

Table 2.70: Summary of participant outcomes by receipt of other antiviral during index hospital stay in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Did not receive other antiviral			
Not randomised to anticoagulation	24	24	2 (8%)
Low dose	337	326	27 (8%)
Intermediate dose	340	335	23 (7%)
Low dose with aspirin	169	165	13 (8%)
Therapeutic dose	48	48	7 (15%)
Received other antiviral			
Not randomised to anticoagulation	8	8	2 (25%)
Low dose	273	272	8 (3%)
Intermediate dose	273	271	2 (1%)
Low dose with aspirin	114	114	7 (6%)
Therapeutic dose	2	2	0 (0%)

Table 2.71: Summary of participant outcomes by receipt of other antiviral during index hospital stay in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Did not receive other antiviral			
Not randomised to antiviral	780	760	63 (8%)
Standard of care	66	66	6 (9%)
Nafamostat	72	72	3 (4%)
Received other antiviral			
Not randomised to antiviral	653	650	16 (2%)
Standard of care	7	7	2 (29%)
Nafamostat	10	10	1 (10%)

Table 2.72: Summary of odds ratios for treatment effects by receipt of other antiviral in the FAS-ITT set.

Received other antiviral	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Did not receive other antivirals	0.37	(0.10, 1.29)	0.45 (0.34)	0.94	0.08
Received other antivirals	0.30	(0.03, 2.83)	0.57 (0.93)	0.85	0.17

Table 2.73: Summary of odds ratio comparisons of treatment effects by receipt of other antiviral in the FAS-ITT set.

Received other antiviral	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Did not receive other antivirals	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Received other antivirals	0.80	(0.09, 6.58)	1.47 (2.19)	0.58

Figure 2.43: Posterior densities of odds ratio for antiviral interventions relative to standard dose by receipt of other antiviral subgroup using FAS-ITT set.

Figure 2.44: Posterior predictive distribution of primary outcome proportion for antiviral interventions by receipt of other antiviral subgroup using FAS-ITT set. Red diamonds indicate sample proportions, black points posterior-predictive medians.

2.2.4.9 Vaccination Status

There were 8 participants randomised to the antiviral domain who had unknown vaccination status none of whom met the primary outcome conditions. Due to small numbers, the effect of Nafamostat amongst those with unknown vaccination status was assumed to be the same as those who were not vaccinated.

Table 2.74: Summary of participant outcomes by whether patient vaccination status at baseline in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Not vaccinated			
Not randomised to anticoagulation	9	9	3 (33%)
Low dose	387	380	24 (6%)
Intermediate dose	371	366	15 (4%)
Low dose with aspirin	212	208	14 (7%)
Therapeutic dose	23	23	4 (17%)
Vaccinated			
Not randomised to anticoagulation	15	15	1 (7%)
Low dose	191	186	3 (2%)
Intermediate dose	220	218	5 (2%)
Low dose with aspirin	42	42	1 (2%)
Therapeutic dose	27	27	3 (11%)
Unknown			
Not randomised to anticoagulation	8	8	0 (0%)
Low dose	32	32	8 (25%)
Intermediate dose	22	22	5 (23%)
Low dose with aspirin	29	29	5 (17%)
Therapeutic dose	0	0	- (-%)

Table 2.75: Summary of participant outcomes by whether patient vaccination status at baseline in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
Not vaccinated			
Not randomised to antiviral	913	897	51 (6%)
Standard of care	39	39	7 (18%)
Nafamostat	50	50	2 (4%)
Vaccinated			
Not randomised to antiviral	437	430	10 (2%)
Standard of care	27	27	1 (4%)
Nafamostat	31	31	2 (6%)
Unknown			
Not randomised to antiviral	83	83	18 (22%)
Standard of care	7	7	0 (0%)
Nafamostat	1	1	0 (0%)

Table 2.76: Summary of odds ratios for treatment effects by patient vaccination status at baseline in the FAS-ITT set.

Vaccination status	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Not vaccinated	0.27	(0.07, 1.01)	0.34 (0.26)	0.97	0.04
Vaccinated	0.91	(0.10, 7.13)	1.59 (2.74)	0.54	0.50
Unknown	0.27	(0.07, 1.01)	0.34 (0.26)	0.97	0.04

Table 2.77: Summary of odds ratio comparisons of treatment effects by patient vaccination status at baseline in the FAS-ITT set.

Vaccination status	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Not vaccinated	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Vaccinated	3.28	(0.40, 25.18)	5.77 (9.67)	0.12
Unknown	1.00	(1.00, 1.00)	1.00 (0.00)	0.00

Figure 2.45: Posterior densities of odds ratio for antiviral interventions relative to standard dose by patient vaccination status at baseline using FAS-ITT set.


Figure 2.46: Posterior predictive distribution of primary outcome proportion for antiviral interventions by vaccination status subgroup using FAS-ITT set. Red diamonds indicate sample proportions, black points posterior-predictive medians.

2.2.4.10 Iatrogenic immunosuppression

No analysis was undertaken as only 6 participants assigned to the antiviral domain had presence of iatrogenic immunosuppression at baseline.

Table 2.78: Summary of participant outcomes by whether patient iatrogenic immunosuppression at baseline in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
No iatrogenic immunosuppression			
Not randomised to anticoagulation	31	31	3 (10%)
Low dose	609	597	35 (6%)
Intermediate dose	607	600	24 (4%)
Low dose with aspirin	283	279	20 (7%)
Therapeutic dose	50	50	7 (14%)
Iatrogenic immunosuppression			
Not randomised to anticoagulation	1	1	1 (100%)
Low dose	1	1	0 (0%)
Intermediate dose	6	6	1 (17%)
Low dose with aspirin	0	0	- (-%)
Therapeutic dose	0	0	- (-%)

Table 2.79: Summary of participant outcomes by whether patient iatrogenic immunosuppression at baseline in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
No iatrogenic immunosuppression			
Not randomised to antiviral	1431	1408	78 (6%)
Standard of care	71	71	8 (11%)
Nafamostat	78	78	3 (4%)
Iatrogenic immunosuppression			
Not randomised to antiviral	2	2	1 (50%)
Standard of care	2	2	0 (0%)
Nafamostat	4	4	1 (25%)

2.2.4.11 D-Dimer

Table 2.80: Summary of participant outcomes by whether patient D-dimer at baseline was above upper limit of normal at baseline in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
D-dimer below upper limit of normal			
Not randomised to anticoagulation	8	8	2 (25%)
Low dose	311	307	15 (5%)
Intermediate dose	336	333	15 (5%)
Low dose with aspirin	184	181	13 (7%)
Therapeutic dose	7	7	0 (0%)
D-dimer above upper limit of normal			
Not randomised to anticoagulation	8	8	1 (12%)
Low dose	182	181	10 (6%)
Intermediate dose	177	176	3 (2%)
Low dose with aspirin	63	62	7 (11%)
Therapeutic dose	10	10	1 (10%)
Unknown			
Not randomised to anticoagulation	16	16	1 (6%)
Low dose	117	110	10 (9%)
Intermediate dose	100	97	7 (7%)
Low dose with aspirin	36	36	0 (0%)
Therapeutic dose	33	33	6 (18%)

Table 2.81: Summary of participant outcomes by whether patient D-dimer at baseline was above upper limit of normal in the FAS-ITT set, antiviral domain.

Antiviral intervention	Patients	Known	Primary outcome
D-dimer below upper limit of normal			
Not randomised to antiviral	809	799	43 (5%)
Standard of care	19	19	1 (5%)
Nafamostat	18	18	1 (6%)
D-dimer above upper limit of normal			
Not randomised to antiviral	373	370	16 (4%)
Standard of care	35	35	4 (11%)
Nafamostat	32	32	2 (6%)
Unknown			
Not randomised to antiviral	251	241	20 (8%)
Standard of care	19	19	3 (16%)
Nafamostat	32	32	1 (3%)

Table 2.82: Summary of odds ratios for treatment effects by D-dimer level at baseline in the FAS-ITT set.

D-dimer out of range	Median	95% CrI	Mean (SD)	$Pr(OR < 1)$	$Pr(OR > 1/1.1)$
Nafamostat					
No	0.45	(0.09, 2.26)	0.64 (0.63)	0.83	0.20
Yes	0.37	(0.06, 2.03)	0.54 (0.58)	0.87	0.15
Unknown	0.21	(0.02, 1.50)	0.35 (0.48)	0.94	0.07

Table 2.83: Summary of odds ratio comparisons of treatment effects by D-dimer level at baseline in the FAS-ITT set.

| D-dimer out of range	Median	95% CrI	Mean (SD)	$Pr(OR < 1)$
Nafamostat				
No	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Yes	0.80	(0.11, 5.39)	1.28 (1.58)	0.59
Unknown	0.45	(0.05, 3.56)	0.79 (1.26)	0.77

Figure 2.47: Posterior densities of odds ratio for antiviral interventions relative to standard dose by D-dimer level at baseline using FAS-ITT set.


Figure 2.48: Posterior predictive distribution of primary outcome proportion for antiviral interventions by D-dimer level using FAS-ITT set. Red diamonds indicate sample proportions, black points posterior-predictive medians.

2.2.4.12 Calendar Time

A randomisation date cut-point of 2021-12-20 was specified.

Table 2.84: Summary of participant outcomes by randomisation date in the FAS-ITT set, anticoagulation domain.

Anticoagulation intervention	Patients	Known	Primary outcome
Randomisation < 2021-12-20			
Not randomised to anticoagulation	22	22	3 (14%)
Low dose	535	526	33 (6%)
Intermediate dose	527	522	24 (5%)
Low dose with aspirin	283	279	20 (7%)
Therapeutic dose	38	38	6 (16%)
Randomisation ≥ 2021-12-20			
Not randomised to anticoagulation	10	10	1 (10%)
Low dose	75	72	2 (3%)
Intermediate dose	86	84	1 (1%)
Low dose with aspirin	0	0	- (-%)
Therapeutic dose	12	12	1 (8%)

Table 2.85: Summary of participant outcomes by randomisation date in the FAS-ITT set, anticoagulation domain.

Antiviral intervention	Patients	Known	Primary outcome
Randomisation < 2021-12-20			
Not randomised to antiviral	1274	1256	76 (6%)
Standard of care	63	63	8 (13%)
Nafamostat	68	68	2 (3%)
Randomisation ≥ 2021-12-20			
Not randomised to antiviral	159	154	3 (2%)
Standard of care	10	10	0 (0%)
Nafamostat	14	14	2 (14%)

Table 2.86: Summary of odds ratios for treatment effects by randomisation date in the FAS-ITT set.

Randomisation date	Median	95% CrI	Mean (SD)	Pr(OR < 1)	Pr(OR > 1/1.1)
Nafamostat					
Randomisation < 2021-12-20	0.30	(0.08, 1.01)	0.36 (0.26)	0.97	0.04
Randomisation ≥ 2021-12-20	1.77	(0.16, 19.07)	3.66 (6.50)	0.32	0.71

Table 2.87: Summary of odds ratio comparisons of treatment effects by randomisation date in the FAS-ITT set.

| Randomisation date	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat				
Randomisation < 2021-12-20	1.00	(1.00, 1.00)	1.00 (0.00)	0.00
Randomisation ≥ 2021-12-20	6.04	(0.61, 56.87)	11.52 (17.91)	0.06

Figure 2.49: Posterior densities of odds ratio for antiviral interventions relative to standard dose by randomisation date subgroup using FAS-ITT set.

Figure 2.50: Posterior predictive distribution of primary outcome proportion for antiviral interventions by randomisation date subgroup using FAS-ITT set. Red diamonds indicate sample proportions and black dot posterior median.

2.3 Secondary Outcomes

For all secondary outcomes, the primary model (the model adjusting for interventions, age group, country, site, and epoch using the relevant outcome model) was fit to the ACS-ITT set. The only sensitivity analysis conducted was to repeat the analyses restricted to contemporaneous controls using a reduced model.

2.3.1 Time to clinical recovery to day 28

This section reports on the analysis for time to clinical recovery. Time to clinical recovery was taken as the first day from the index admission at which the patient had a WHO outcome score of 3 or less. For participants whose WHO outcome score was greater than 3 on the day of discharge, their day of recovery was counted as the first day after discharge, e.g. if discharged on day 7 with a daily WHO score of 4, then time to recovery was quantified as 8. Death was treated as a competing-risk to recovery. If recovery and death reportedly occurred on the same day (e.g. daily status WHO scale $<$ 4 but discharge outcome of death on same day), then the patient was considered to have died on that day without recovery. No adjustment was made for participants who recovered but then subsequently died (i.e. only the first event was considered; any such patients were just counted as recovered on the relevant day). No allowance was made for participants who discharged against medical advice (treated as recovered following discharge).

The analysis of the time to clinical recovery to day 28 outcome used a discrete-time competing risk time-to-event model (multinomial logistic regression). The events of interest were death or recovery. Baseline cause-specific hazards were modelled separately for death and recovery with some smoothing enforced across adjacent time points via a first order random walk prior on the logit intercept terms.

This modelling approach deviated from that specified in the SAP which did not account for the competing risk of death.

2.3.1.1 FAS-ITT

- **Model**: multinomial logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, epoch
- **Set**: FAS-ITT

Table 2.88: Summary for time to recovery (TTR) or death to day 28, anticoagulation domain, FAS-ITT

Intervention	Randomised	Known	Died	Recovered	Unrecovered	TTR, Median (Q1, Q3)
Not randomised	32	32	0 (0.0)	30 (93.8)	2 (6.2)	6 (5.00, 8.75)
Low	610	610	15 (2.5)	592 (97.0)	3 (0.5)	6 (4.00, 7.00)
Intermediate	613	613	10 (1.6)	598 (97.6)	5 (0.8)	6 (4.00, 7.00)
Low with aspirin	283	283	9 (3.2)	271 (95.8)	3 (1.1)	6 (4.00, 8.00)
Therapeutic	50	50	4 (8.0)	46 (92.0)	0 (0.0)	6 (4.25, 9.00)

Table 2.89: Summary for time to recovery (TTR) or death to day 28, antiviral domain, FAS-ITT

Intervention	Randomised	Known	Died	Recovered	Unrecovered	TTR, Median (Q1, Q3)
Not randomised	1433	1433	38 (2.7)	1386 (96.7)	9 (0.6)	6 (4.00, 7.00)
Standard of care	73	73	0 (0.0)	71 (97.3)	2 (2.7)	6 (5.00, 9.00)
Nafamostat	82	82	0 (0.0)	80 (97.6)	2 (2.4)	6 (5.00, 9.00)

Figure 2.51: Observed progression of patients with respect to death and recovery, anticoagulation domain, FAS-ITT.

Figure 2.52: Observed progression of patients with respect to death and recovery, antiviral domain, FAS-ITT.

Table 2.90: Posterior summary of cause-specific odds ratios for recovery or death to day 28, FAS-ITT.

Factor	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Recovery				
Nafamostat	1.05	(0.73, 1.54)	1.07 (0.21)	0.59
Intermediate	1.12	(0.98, 1.30)	1.13 (0.08)	0.95
Low with aspirin	1.05	(0.86, 1.24)	1.05 (0.10)	0.68
Therapeutic	0.84	(0.56, 1.25)	0.85 (0.17)	0.18
Ineligible aspirin	0.80	(0.50, 1.20)	0.80 (0.18)	0.14
Age $\geq$ 60	0.66	(0.58, 0.77)	0.67 (0.05)	0.00
Female	1.02	(0.90, 1.15)	1.02 (0.07)	0.62
Oxygen requirement	0.61	(0.53, 0.70)	0.61 (0.04)	0.00
Australia/New Zealand	0.85	(0.46, 1.42)	0.86 (0.24)	0.25
Nepal	0.78	(0.28, 2.40)	0.93 (0.64)	0.33
Death				
Nafamostat	0.85	(0.08, 8.77)	1.83 (2.88)	0.45
Intermediate	0.58	(0.25, 1.33)	0.64 (0.29)	0.12
Low with aspirin	0.73	(0.30, 1.80)	0.81 (0.41)	0.23
Therapeutic	3.87	(0.86, 18.43)	5.09 (4.46)	0.96
Ineligible aspirin	3.70	(0.89, 14.30)	4.67 (3.69)	0.96
Age $\geq$ 60	0.88	(0.40, 2.01)	0.96 (0.42)	0.38
Female	0.27	(0.11, 0.61)	0.29 (0.12)	0.00
Oxygen requirement	1.65	(0.76, 3.79)	1.79 (0.83)	0.89
Australia/New Zealand	0.52	(0.10, 2.52)	0.71 (0.69)	0.20
Nepal	2.02	(0.41, 8.53)	2.62 (2.10)	0.80

Figure 2.53: Cause-specific baseline hazard posterior summaries, FAS-ITT.

Recovery

Figure 2.54: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on recovery to day 28 for the outcome model fit to the FAS-ITT set.

Death

Figure 2.55: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on death to day 28 for the outcome model fit to the FAS-ITT set.

2.3.1.2 AVS-ITT

- **Model**: multinomial logistic regression
- **Terms**: antiviral intervention, anticoagulation intervention, age group, sex, oxygen requirement, CRP tertile
- **Set**: AVS-ITT

Figure 2.56: Observed progression of patients with respect to death and recovery, anticoagulation domain, AVS-ITT.

Table 2.91: Posterior summary of cause-specific odds ratios for recovery or death to day 28, AVS-ITT.

Factor	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Recovery				
Nafamostat	0.98	(0.65, 1.49)	1.00 (0.22)	0.45
Intermediate	0.62	(0.26, 1.47)	0.68 (0.32)	0.13
Low with aspirin	1.52	(0.50, 4.18)	1.74 (0.99)	0.78
Therapeutic	0.95	(0.39, 2.33)	1.06 (0.51)	0.46
Age ≥ 60	0.32	(0.19, 0.49)	0.32 (0.08)	0.00
Female	0.99	(0.67, 1.45)	1.01 (0.20)	0.47
Oxygen requirement	0.84	(0.55, 1.34)	0.87 (0.20)	0.22
CRP (2nd tertile)	0.61	(0.38, 1.01)	0.63 (0.16)	0.03
CRP (3rd tertile)	0.78	(0.46, 1.33)	0.81 (0.22)	0.18
CRP (unknown)	1.44	(0.70, 2.86)	1.53 (0.57)	0.84
Death				
Nafamostat	0.99	(0.08, 13.33)	2.36 (4.53)	0.50
Intermediate	0.99	(0.07, 17.13)	2.82 (7.74)	0.50
Low with aspirin	1.03	(0.06, 16.57)	2.90 (7.56)	0.51
Therapeutic	0.98	(0.07, 14.22)	2.47 (5.41)	0.49
Age ≥ 60	0.70	(0.01, 61.81)	11.99 (225.42)	0.44
Female	0.72	(0.01, 48.34)	7.88 (55.36)	0.44
Oxygen requirement	0.57	(0.01, 46.23)	8.28 (81.96)	0.40
CRP (2nd tertile)	0.73	(0.01, 69.18)	10.01 (56.84)	0.44
CRP (3rd tertile)	0.81	(0.01, 74.23)	16.58 (357.11)	0.46
CRP (unknown)	0.90	(0.01, 97.26)	16.62 (174.56)	0.49

Figure 2.57: Cause-specific baseline hazard posterior summaries, AVS-ITT.

2.3.1.3 ACS-ITT

- **Model**: multinomial logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, epoch
- **Set**: ACS-ITT

Figure 2.58: Observed progression of patients with respect to death and recovery, antiviral domain, ACS-ITT.

Table 2.92: Posterior summary of cause-specific odds ratios for recovery or death to day 28, ACS-ITT.

Factor	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Recovery				
Nafamostat	1.27	(0.84, 1.90)	1.31 (0.28)	0.87
Intermediate	1.12	(0.97, 1.27)	1.12 (0.08)	0.94
Low with aspirin	1.04	(0.85, 1.23)	1.04 (0.10)	0.64
Therapeutic	0.80	(0.54, 1.18)	0.82 (0.16)	0.14
Ineligible aspirin	0.77	(0.48, 1.18)	0.80 (0.19)	0.15
Age $\geq$ 60	0.68	(0.59, 0.78)	0.68 (0.05)	0.00
Oxygen requirement	0.58	(0.51, 0.67)	0.58 (0.04)	0.00
Australia/New Zealand	0.92	(0.51, 1.68)	0.96 (0.30)	0.38
Nepal	0.80	(0.25, 2.47)	0.92 (0.62)	0.30
Death				
Nafamostat	1.07	(0.11, 11.16)	2.16 (3.58)	0.52
Intermediate	0.62	(0.25, 1.50)	0.69 (0.32)	0.14
Low with aspirin	0.91	(0.39, 2.18)	1.00 (0.45)	0.42
Therapeutic	3.00	(0.72, 11.61)	3.79 (2.94)	0.94
Ineligible aspirin	4.17	(1.08, 14.91)	5.23 (3.65)	0.98
Age $\geq$ 60	0.87	(0.41, 1.87)	0.95 (0.39)	0.38
Oxygen requirement	1.24	(0.56, 2.95)	1.36 (0.62)	0.69
Australia/New Zealand	0.57	(0.11, 2.49)	0.75 (0.65)	0.24
Nepal	1.79	(0.34, 8.89)	2.45 (2.43)	0.77

Figure 2.59: Cause-specific baseline hazard posterior summaries, ACS-ITT.

Recovery

Figure 2.60: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on recovery to day 28 for the outcome model fit to the ACS-ITT set.

Death

Figure 2.61: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on death to day 28 for the outcome model fit to the ACS-ITT set.

2.3.2 WHO 8-point ordinal outcome scale at day 28

This section reports on the analysis of the secondary outcome: WHO outcome scale at day 28. The model is coded so that an odds ratio less than 1 implies a benefit (reduction in odds of having a higher WHO score at day 28).

Table 2.93 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. Similarly for the antiviral arms in Table 2.94. For two participants randomised to the antiviral domain, their day 28 WHO outcome score was missing (as in Table 2.94), but they were known to be out of hospital. Therefore, their outcome was actually censored in $\{1, 2\}$. They were excluded as missing in the results below. A sensitivity analysis (not reported) included them as censored observations with no difference in results.

Table 2.93: Summary of WHO scale at 28 by anticoagulation treatment group, FAS-ITT.

Anticoagulation intervention	Patients	Known	Deaths	Hospitalised	WHO, Median (Q1, Q3)
Not randomised to anticoagulation	32	32	0 (0%)	4 (12%)	2 (1, 2)
Low-dose	610	597	19 (3%)	7 (1%)	1 (1, 2)
Intermediate-dose	613	607	15 (2%)	5 (1%)	1 (1, 2)
Low-dose with aspirin	283	281	10 (4%)	5 (2%)	1 (1, 2)
Therapeutic-dose	50	50	6 (12%)	1 (2%)	1 (1, 2)
Overall	**1588**	**1567**	**50 (3%)**	**22 (1%)**	**1 (1, 2)**

Table 2.94: Summary of WHO scale at 28 by antiviral treatment group, FAS-ITT.

Antiviral intervention	Patients	Known	Deaths	Hospitalised	WHO, Median (Q1, Q3)
Not randomised to antiviral	1433	1414	50 (4%)	13 (1%)	1 (1, 2)
Standard of care	73	72	0 (0%)	6 (8%)	2 (1, 2)
Nafamostat	82	81	0 (0%)	3 (4%)	1 (1, 2)
Overall	**1588**	**1567**	**50 (3%)**	**22 (1%)**	**1 (1, 2)**

2.3.2.1 FAS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: FAS-ITT

Figure 2.62 and Figure 2.63 report on the distribution of day 28 WHO score.

Figure 2.62: Observed distribution of WHO outcome scale at day 28 by anticoagulation treatment group, FAS-ITT.

The model parameters (odds ratios) are summarised in Table 2.95 for the fixed-effect terms and in Figure 2.65 for the site and epoch specific terms.

Figure 2.63: Observed distribution of WHO outcome scale at day 28 by antiviral treatment group, FAS-ITT.

Table 2.95: Summary of model parameters (fixed-effects odds-ratios) for WHO outcome scale at day 28 outcome model fit to the FAS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.67	(0.35, 1.27)	0.71 (0.24)	0.89
Intermediate-dose	0.80	(0.60, 1.07)	0.81 (0.12)	0.94
Low-dose with aspirin	0.73	(0.51, 1.06)	0.75 (0.14)	0.95
Therapeutic-dose	1.70	(0.83, 3.42)	1.81 (0.67)	0.07
Ineligible aspirin	1.64	(0.75, 3.54)	1.77 (0.72)	0.10
Age $\geq$ 60	2.49	(1.91, 3.26)	2.52 (0.35)	0.00
Female	0.94	(0.73, 1.22)	0.95 (0.13)	0.67
Oxygen requirement	2.12	(1.59, 2.82)	2.14 (0.32)	0.00
Australia/New Zealand	1.30	(0.42, 3.96)	1.53 (0.94)	0.32
Nepal	0.56	(0.17, 1.91)	0.68 (0.51)	0.84

Figure 2.64: Posterior densities for the treatment effect odds ratios, FAS-ITT.

Figure 2.65: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on WHO outcome scale at day 28 for the outcome model fit to the FAS-ITT set.

2.3.2.2 AVS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: antiviral intervention, anticoagulation intervention, age group, sex, oxygen requirement, CRP tertile
- **Set**: AVS-ITT

Figure 2.66 presents the distribution of day 28 WHO score by anticoagulation intervention for AVS-ITT.

Figure 2.66: Observed distribution of WHO outcome scale at day 28 by anticoagulation treatment group, AVS-ITT.

Table 2.96: Summary of model parameters (fixed-effects odds-ratios) for WHO outcome scale at day 28 outcome model fit to the AVS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.72	(0.36, 1.45)	0.77 (0.28)	0.82
Intermediate-dose	1.27	(0.56, 2.87)	1.38 (0.60)	0.28
Low-dose with aspirin	0.80	(0.19, 3.20)	1.03 (0.83)	0.62
Therapeutic-dose	1.97	(0.65, 5.87)	2.30 (1.40)	0.11
Age ≥ 60	3.77	(1.77, 8.24)	4.08 (1.70)	0.00
Female	1.29	(0.65, 2.53)	1.37 (0.49)	0.23
Oxygen requirement	1.16	(0.55, 2.54)	1.27 (0.51)	0.34
CRP (2nd tertile)	0.81	(0.35, 1.86)	0.89 (0.39)	0.69
CRP (3rd tertile)	0.79	(0.33, 1.84)	0.86 (0.39)	0.71
CRP (unknown)	0.84	(0.26, 2.54)	0.98 (0.61)	0.62

Figure 2.67: Posterior densities for the treatment effect odds ratios, AVS-ITT.

2.3.2.3 ACS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: ACS-ITT

Figure 2.68 presents the distribution of day 28 WHO score by antiviral intervention for ACS-ITT.

Figure 2.68: Observed distribution of WHO outcome scale at day 28 by antiviral treatment group, ACS-ITT.

Table 2.97: Summary of model parameters (fixed-effects odds-ratios) for WHO outcome scale at day 28 outcome model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.67	(0.32, 1.40)	0.72 (0.28)	0.86
Intermediate-dose	0.81	(0.60, 1.07)	0.81 (0.12)	0.93
Low-dose with aspirin	0.73	(0.51, 1.04)	0.74 (0.14)	0.96
Therapeutic-dose	1.73	(0.85, 3.47)	1.84 (0.68)	0.07
Ineligible aspirin	1.68	(0.76, 3.65)	1.81 (0.75)	0.10
Age $\geq$ 60	2.36	(1.80, 3.10)	2.39 (0.33)	0.00
Female	0.94	(0.73, 1.21)	0.95 (0.12)	0.67
Oxygen requirement	2.21	(1.64, 2.97)	2.23 (0.34)	0.00
Australia/New Zealand	1.14	(0.35, 3.58)	1.35 (0.86)	0.41
Nepal	0.60	(0.19, 2.05)	0.73 (0.56)	0.81

Figure 2.69: Posterior densities for the treatment effect odds ratios, ACS-ITT.

Figure 2.70: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on WHO outcome scale at day 28 for the outcome model fit to the ACS-ITT set.

144

2.3.3 All-cause mortality to day 28

This section reports on the analysis of the secondary outcome: all-cause mortality to day 28. For this outcome, participants who died within 28 days were coded to have a value of 1, and those who did not, to have a value of 0. The model is coded so that an odds ratio less than 1 implies a benefit (reduction in odds of death by day 28).

Table 2.98 and Table 2.99 presents the number of participants where the outcome was observed by the allocated anticoagulation (for ACS-ITT) arm and antiviral arm (for AVS-ITT) respectively.

Table 2.98: Summary of mortality by day 28 by treatment group, ACS-ITT.

n (%)	Low dose	Intermediate dose	Low dose with aspirin	Therapeutic dose	Overall
Randomised	610	613	283	50	1556
Outcome missing	12 (2.0)	5 (0.8)	2 (0.7)	0 (0.0)	19 (1.2)
Outcome observed	598 (98.0)	608 (99.2)	281 (99.3)	50 (100.0)	1537 (98.8)
Died within 28 days	19 (3.2)	15 (2.5)	10 (3.6)	6 (12.0)	50 (3.3)

Table 2.99: Summary of mortality by day 28 by treatment group, AVS-ITT.

n (%)	Standard of care	Nafamostat	Overall
Randomised	73	82	155
Outcome missing	0 (0.0)	0 (0.0)	0 (0.0)
Outcome observed	73 (100.0)	82 (100.0)	155 (100.0)
Died within 28 days	0 (0.0)	0 (0.0)	0 (0.0)

2.3.3.1 FAS-ITT

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: FAS-ITT

The model parameters (odds ratios) are summarised in Table 2.101 for the fixed-effect terms and in Figure 2.74 for the site and epoch specific terms.

Table 2.100: Summary of model parameters (fixed-effects odds-ratios) for mortality by day 28 primary model fit to the FAS-ITT set.

| Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.88	(0.09, 8.47)	1.68 (2.90)	0.55
Intermediate-dose	0.79	(0.39, 1.61)	0.84 (0.32)	0.74
Low-dose with aspirin	0.80	(0.35, 1.79)	0.87 (0.38)	0.70
Therapeutic-dose	3.93	(1.18, 13.12)	4.74 (3.18)	0.01
Ineligible aspirin	4.69	(1.15, 17.33)	5.83 (4.34)	0.02
Age $\geq$ 60	2.00	(1.05, 3.77)	2.10 (0.69)	0.02
Female	0.34	(0.16, 0.68)	0.36 (0.14)	1.00
Oxygen requirement	3.24	(1.69, 6.28)	3.43 (1.20)	0.00
Australia/New Zealand	0.53	(0.11, 2.36)	0.71 (0.62)	0.79
Nepal	2.49	(0.56, 9.59)	3.14 (2.51)	0.11

Figure 2.71: Posterior densities for the treatment effect odds ratios, FAS-ITT.

Figure 2.72: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 mortality for the primary model fit to the FAS-ITT set.

147

2.3.3.2 AVS-ITT

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, age group, sex, oxygen requirement, CRP tertile
- **Set**: AVS-ITT

No deaths were observed when restricting to the AVS-ITT set, therefore the data provides no information on the model parameters. Therefore this model is not reported.

2.3.3.3 ACS-ITT

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: ACS-ITT

Table 2.101: Summary of model parameters (fixed-effects odds-ratios) for mortality by day 28 primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.83	(0.08, 8.53)	1.67 (2.89)	0.56
Intermediate-dose	0.80	(0.38, 1.63)	0.85 (0.32)	0.73
Low-dose with aspirin	0.82	(0.35, 1.85)	0.89 (0.39)	0.68
Therapeutic-dose	4.00	(1.20, 13.50)	4.87 (3.34)	0.01
Ineligible aspirin	4.49	(1.11, 16.55)	5.60 (4.19)	0.02
Age ≥ 60	2.04	(1.09, 3.82)	2.15 (0.71)	0.01
Female	0.34	(0.16, 0.69)	0.36 (0.14)	1.00
Oxygen requirement	3.24	(1.70, 6.34)	3.43 (1.20)	0.00
Australia/New Zealand	0.54	(0.11, 2.45)	0.72 (0.66)	0.79
Nepal	2.57	(0.56, 9.98)	3.25 (2.58)	0.10

Figure 2.73: Posterior densities for the treatment effect odds ratios, ACS-ITT.

Figure 2.74: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 mortality for the primary model fit to the ACS-ITT set.

2.3.4 Days alive and free of hospital to day 28

This section reports on the analysis of the secondary outcome: days alive and free of hospital (DAFH) to day 28. For this outcome, participants who died within 28 days were coded to have 0 DAFH. The model is coded so that an odds ratio greater than 1 implies a benefit (increased odds of more days alive and free of hospital).

Table 2.102 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. Similarly, Table 2.103 for the antiviral domain.

Two participants had missing number of days alive and free of hospital, however, they were known to be alive and out of hospital on day 28. One participant spent 8 days in hospital as part of their index admission and the other spent 5. Therefore, for these two participants their days alive and free of hospital were censored between [1, 20] and [1, 23] days respectively, with 20 and 23 most likely (i.e. no readmission to hospital). For the analyses these two participants were excluded as missing. A sensitivity analysis (not reported) included them as censored observations with no difference in results.

Figure 2.75: Observed overall distribution of days alive and free of hospital at day 28, FAS-ITT.

Table 2.102: Summary of days alive and free of hospital to day 28 by treatment group, FAS-ITT.

Anticoagulation intervention	Patients	Known	Deaths	DAFH, Median (Q1, Q3)
Not randomised to anticoagulation	32	31	0 (0%)	22 (18, 24)
Low-dose	610	597	19 (3%)	23 (21, 24)
Intermediate-dose	613	607	15 (2%)	23 (21, 24)
Low-dose with aspirin	283	280	10 (4%)	22 (20, 24)
Therapeutic-dose	50	50	6 (12%)	22 (19, 24)
Overall	**1588**	**1565**	**50 (3%)**	**23 (21, 24)**

Table 2.103: Summary of days alive and free of hospital to day 28 by treatment group, FAS-ITT.

Antiviral intervention	Patients	Known	Deaths	DAFH, Median (Q1, Q3)
Not randomised to antiviral	1433	1412	50 (4%)	23 (21, 24)
Standard of care	73	72	0 (0%)	22 (20, 24)
Nafamostat	82	81	0 (0%)	22 (19, 24)
Overall	**1588**	**1565**	**50 (3%)**	**23 (21, 24)**

2.3.4.1 FAS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: FAS-ITT

The observed distribution of DAFH by domain treatment arm is shown in Figure 2.76 and Figure 2.77.

Figure 2.76: Observed distribution of days alive and free of hospital at day 28 by anticoagulation treatment group, FAS-ITT.

Figure 2.77: Observed distribution of days alive and free of hospital at day 28 by antiviral treatment group, AVS-ITT.

Table 2.104: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of hospital to day 28 outcome model fit to the FAS-ITT set.

| Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Nafamostat	1.06	(0.59, 1.91)	1.11 (0.34)	0.58
Intermediate-dose	1.17	(0.96, 1.43)	1.17 (0.12)	0.94
Low-dose with aspirin	1.08	(0.82, 1.41)	1.09 (0.15)	0.70
Therapeutic-dose	0.65	(0.36, 1.18)	0.69 (0.21)	0.08
Ineligible aspirin	1.09	(0.57, 2.06)	1.14 (0.39)	0.60
Age ≥ 60	0.61	(0.50, 0.75)	0.61 (0.07)	0.00
Female	1.14	(0.96, 1.36)	1.15 (0.10)	0.93
Oxygen requirement	0.46	(0.37, 0.58)	0.47 (0.05)	0.00
Australia/New Zealand	1.00	(0.46, 2.20)	1.08 (0.46)	0.50
Nepal	0.84	(0.27, 3.01)	1.04 (0.78)	0.38

Figure 2.78: Posterior densities for the treatment effect odds ratios, FAS-ITT.

Figure 2.79: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on days alive and free of hospital to day 28 for the outcome model fit to the FAS-ITT set.

2.3.4.2 AVS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, age group, sex, oxygen requirement, CRP tertile
- **Set**: AVS-ITT

Figure 2.80: Observed distribution of days alive and free of hospital at day 28 by anticoagulation treatment group, AVS-ITT.

Table 2.105: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of hospital to day 28 primary model fit to the AVS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Nafamostat	0.81	(0.44, 1.49)	0.85 (0.27)	0.25
Intermediate-dose	3.28	(1.57, 6.85)	3.52 (1.37)	1.00
Low-dose with aspirin	2.35	(0.67, 8.20)	2.89 (2.07)	0.91
Therapeutic-dose	2.00	(0.74, 5.41)	2.27 (1.25)	0.91
Age ≥ 60	0.18	(0.09, 0.38)	0.20 (0.07)	0.00
Female	0.93	(0.51, 1.69)	0.97 (0.30)	0.40
Required oxygen	0.71	(0.36, 1.37)	0.75 (0.26)	0.16
CRP (2nd tertile)	0.56	(0.26, 1.17)	0.60 (0.24)	0.06
CRP (3rd tertile)	0.75	(0.35, 1.58)	0.80 (0.32)	0.22
CRP (unknown)	1.73	(0.66, 4.60)	1.96 (1.05)	0.87

Figure 2.81: Posterior densities for the treatment effect odds ratios, AVS-ITT.

2.3.4.3 ACS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: ACS-ITT

Figure 2.82: Observed distribution of days alive and free of hospital at day 28 by antiviral treatment group, ACS-ITT.

Table 2.106: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of hospital to day 28 primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Nafamostat	1.02	(0.52, 2.00)	1.08 (0.38)	0.52
Intermediate-dose	1.17	(0.96, 1.43)	1.18 (0.12)	0.94
Low-dose with aspirin	1.08	(0.82, 1.42)	1.09 (0.15)	0.71
Therapeutic-dose	0.66	(0.36, 1.20)	0.69 (0.22)	0.09
Ineligible aspirin	1.13	(0.59, 2.16)	1.19 (0.40)	0.65
Age ≥ 60	0.61	(0.49, 0.75)	0.61 (0.07)	0.00
Female	1.16	(0.96, 1.39)	1.16 (0.11)	0.93
Oxygen requirement	0.47	(0.37, 0.58)	0.47 (0.05)	0.00
Australia/New Zealand	1.13	(0.50, 2.60)	1.24 (0.55)	0.61
Nepal	0.82	(0.26, 2.93)	1.02 (0.79)	0.37

Figure 2.83: Posterior densities for the treatment effect odds ratios, ACS-ITT.

2.3.5 Days alive and free of invasive or non-invasive ventilation to day 28

This section reports on the analysis of the secondary outcome: days alive and free invasive or non-invasive ventilation (DAFV) to day 28. For this outcome, participants who died within 28 days were coded to have 0 DAFV.

Table 2.107 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. Similarly, Table 2.108 for the antiviral domain.

Figure 2.84: Observed overall distribution of days alive and free of hospital at day 28, FAS-ITT.

Table 2.107: Summary of days alive and free of ventilation to day 28 by anticoagulation treatment group, FAS-ITT.

Anticoagulation intervention	Patients	Known	Deaths	Any ventilation	DAFV, Median (Q1, Q3)
Not randomised to anticoagulation	32	26	0 (0%)	4 (15%)	28 (28, 28)
Low-dose	610	598	19 (3%)	34 (6%)	28 (28, 28)
Intermediate-dose	613	606	15 (2%)	23 (4%)	28 (28, 28)
Low-dose with aspirin	283	281	10 (4%)	18 (6%)	28 (28, 28)
Therapeutic-dose	50	50	6 (12%)	7 (14%)	28 (28, 28)
Overall	**1588**	**1561**	**50 (3%)**	**86 (6%)**	**28 (28, 28)**

Table 2.108: Summary of days alive and free of ventilation to day 28 by antiviral treatment group, FAS-ITT.

Antiviral intervention	Patients	Known	Deaths	Any ventilation	DAFV, Median (Q1, Q3)
Not randomised to antiviral	1433	1414	50 (4%)	74 (5%)	28 (28, 28)
Standard of care	73	68	0 (0%)	8 (12%)	28 (28, 28)
Nafamostat	82	79	0 (0%)	4 (5%)	28 (28, 28)
Overall	**1588**	**1561**	**50 (3%)**	**86 (6%)**	**28 (28, 28)**

2.3.5.1 FAS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: FAS-ITT

The observed distribution of DAFV by domain treatment arm is shown in Figure 2.85 and Figure 2.86.

Figure 2.85: Observed distribution of days alive and free of ventilation at day 28 by anticoagulation treatment group, FAS-ITT.

Figure 2.86: Observed distribution of days alive and free of ventilation at day 28 by antiviral treatment group, FAS-ITT.

Table 2.109: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of ventilation to day 28 primary model fit to the FAS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Nafamostat	2.52	(0.76, 8.72)	3.09 (2.20)	0.94
Intermediate-dose	1.48	(0.84, 2.62)	1.55 (0.46)	0.91
Low-dose with aspirin	1.19	(0.64, 2.27)	1.26 (0.42)	0.70
Therapeutic-dose	0.34	(0.12, 0.96)	0.40 (0.23)	0.02
Ineligible aspirin	0.32	(0.10, 1.14)	0.39 (0.30)	0.04
Age $\geq$ 60	0.53	(0.32, 0.87)	0.55 (0.14)	0.01
Female	1.81	(1.10, 3.05)	1.88 (0.50)	0.99
Oxygen requirement	0.27	(0.15, 0.45)	0.27 (0.07)	0.00
Australia/New Zealand	1.12	(0.29, 4.61)	1.45 (1.21)	0.56
Nepal	0.74	(0.21, 2.96)	0.95 (0.77)	0.33

Figure 2.87: Posterior densities for the treatment effect odds ratios, FAS-ITT.

Figure 2.88: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on days alive and free of ventilation to day 28 for the primary model fit to the FAS-ITT set.

2.3.5.2 AVS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, age group, sex, oxygen requirement, CRP tertile
- **Set**: AVS-ITT

Figure 2.89: Observed distribution of days alive and free of ventilation at day 28 by anticoagulation treatment group, AVS-ITT.

Table 2.110: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of ventilation to day 28 primary model fit to the AVS-ITT set.

| Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Nafamostat	2.87	(0.85, 10.09)	3.56 (2.65)	0.96
Intermediate-dose	1.46	(0.34, 6.56)	1.95 (1.76)	0.70
Low-dose with aspirin	1.26	(0.17, 9.82)	2.18 (3.21)	0.58
Therapeutic-dose	1.20	(0.21, 7.12)	1.81 (2.08)	0.58
Age ≥ 60	0.59	(0.14, 2.69)	0.80 (0.73)	0.24
Female	1.62	(0.44, 6.89)	2.12 (1.86)	0.76
Required oxygen	0.64	(0.12, 2.76)	0.84 (0.74)	0.28
CRP (2nd tertile)	0.43	(0.09, 1.95)	0.57 (0.51)	0.13
CRP (3rd tertile)	1.49	(0.27, 8.78)	2.26 (2.85)	0.68
CRP (unknown)	6.76	(0.38, 334.94)	55.64 (605.99)	0.89
Nepal	1.28	(0.20, 8.46)	2.04 (2.56)	0.60

167

Figure 2.90: Posterior densities for the treatment effect odds ratios, AVS-ITT.

2.3.5.3 ACS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: ACS-ITT

Figure 2.91: Observed distribution of days alive and free of ventilation at day 28 by antiviral treatment group, ACS-ITT.

Table 2.111: Summary of model parameters (fixed-effects odds-ratios) for days alive and free of ventilation to day 28 primary model fit to the ACS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR > 1)
Nafamostat	3.83	(0.93, 17.32)	5.18 (4.76)	0.97
Intermediate-dose	1.49	(0.85, 2.64)	1.56 (0.46)	0.92
Low-dose with aspirin	1.19	(0.63, 2.31)	1.27 (0.43)	0.71
Therapeutic-dose	0.34	(0.12, 1.00)	0.40 (0.23)	0.03
Ineligible aspirin	0.28	(0.08, 1.07)	0.35 (0.28)	0.03
Age ≥ 60	0.53	(0.32, 0.89)	0.55 (0.14)	0.01
Female	1.82	(1.10, 3.11)	1.90 (0.52)	0.99
Oxygen requirement	0.26	(0.15, 0.44)	0.27 (0.07)	0.00
Australia/New Zealand	1.40	(0.35, 6.28)	1.89 (1.76)	0.68
Nepal	0.68	(0.19, 2.83)	0.88 (0.75)	0.29

Figure 2.92: Posterior densities for the treatment effect odds ratios, ACS-ITT.

2.3.6 Presence of patient reported shortness of breath at day 28

This section reports on the analysis of the secondary outcome: patient reported shortness of breath at day 28. For this outcome, participants who died within 28 days were coded to have a missing value, so this outcome reflects shortness of breath at day 28 amongst patients who survived to at least day 28. The model is coded so that an odds ratio less than 1 implies a benefit (reduction in odds of shortness of breath at day 28).

Table 2.112 presents the number of participants where the outcome was observed by the allocated anticoagulation arm. Similarly for the antiviral arms in Table 2.113.

Table 2.112: Summary of WHO scale at 28 by anticoagulation treatment group, ACS-ITT.

n (%)	Patients	Known	Missing	Shortness of breath day 28
Low dose	610	577 (94.6)	33 (5.4)	115 (19.9)
Intermediate dose	613	584 (95.3)	29 (4.7)	110 (18.8)
Low dose with aspirin	283	271 (95.8)	12 (4.2)	59 (21.8)
Therapeutic dose	50	44 (88.0)	6 (12.0)	11 (25.0)
Overall	**1556**	**1476 (94.9)**	**80 (5.1)**	**295 (20.0)**

Table 2.113: Summary of WHO scale at 28 by antiviral treatment group, AVS-ITT.

n (%)	Patients	Known	Missing	Shortness of breath day 28
Standard of care	73	67 (91.8)	6 (8.2)	35 (52.2)
Nafamostat	82	73 (89.0)	9 (11.0)	36 (49.3)
Overall	**155**	**140 (90.3)**	**15 (9.7)**	**71 (50.7)**

2.3.6.1 FAS-ITT

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: FAS-ITT

Table 2.114: Summary of model parameters (fixed-effects odds-ratios) for shortness of breath at day 28 primary model fit to the FAS-ITT set.

| Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.85	(0.35, 2.07)	0.94 (0.45)	0.64
Intermediate-dose	0.77	(0.54, 1.09)	0.78 (0.14)	0.93
Low-dose with aspirin	1.17	(0.75, 1.83)	1.20 (0.27)	0.24
Therapeutic-dose	0.95	(0.37, 2.39)	1.05 (0.53)	0.55
Ineligible aspirin	1.23	(0.42, 3.42)	1.40 (0.79)	0.35
Age ≥ 60	2.04	(1.45, 2.86)	2.07 (0.36)	0.00
Female	1.02	(0.75, 1.40)	1.04 (0.17)	0.44
Oxygen requirement	1.28	(0.88, 1.86)	1.30 (0.25)	0.10
Australia/New Zealand	2.29	(0.59, 8.51)	2.87 (2.18)	0.11
Nepal	0.50	(0.12, 2.50)	0.70 (0.69)	0.81

Figure 2.93: Posterior densities for the treatment effect odds ratios, FAS-ITT.

Figure 2.94: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 shortness of breath for the primary model fit to the FAS-ITT set.

2.3.6.2 AVS-ITT

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, age group, sex, oxygen requirement, CRP tertile
- **Set**: AVS-ITT

Table 2.115: Summary of model parameters (fixed-effects odds-ratios) for shortness of breath at day 28 primary model fit to the AVS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.76	(0.35, 1.62)	0.82 (0.33)	0.76
Intermediate-dose	0.78	(0.32, 1.88)	0.86 (0.41)	0.71
Low-dose with aspirin	0.58	(0.13, 2.38)	0.75 (0.61)	0.77
Therapeutic-dose	1.65	(0.51, 5.57)	2.00 (1.36)	0.20
Age ≥ 60	3.04	(1.33, 7.34)	3.37 (1.57)	0.00
Female	1.16	(0.55, 2.51)	1.26 (0.51)	0.35
Oxygen requirement	2.56	(1.09, 6.20)	2.83 (1.32)	0.01
CRP (2nd tertile)	0.83	(0.32, 2.18)	0.94 (0.49)	0.65
CRP (3rd tertile)	0.73	(0.28, 1.89)	0.82 (0.42)	0.74
CRP (unknown)	1.08	(0.30, 3.88)	1.34 (0.98)	0.45


Figure 2.95: Posterior densities for the treatment effect odds ratios, AVS-ITT.

2.3.6.3 ACS-ITT

- **Model**: logistic regression
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: ACS-ITT

Table 2.116: Summary of model parameters (fixed-effects odds-ratios) for shortness of breath at day 28 primary model fit to the ACS-ITT set.

| Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.85	(0.35, 2.07)	0.94 (0.45)	0.64
Intermediate-dose	0.77	(0.54, 1.09)	0.78 (0.14)	0.93
Low-dose with aspirin	1.17	(0.75, 1.83)	1.20 (0.27)	0.24
Therapeutic-dose	0.95	(0.37, 2.39)	1.05 (0.53)	0.55
Ineligible aspirin	1.23	(0.42, 3.42)	1.40 (0.79)	0.35
Age ≥ 60	2.04	(1.45, 2.86)	2.07 (0.36)	0.00
Female	1.02	(0.75, 1.40)	1.04 (0.17)	0.44
Oxygen requirement	1.28	(0.88, 1.86)	1.30 (0.25)	0.10
Australia/New Zealand	2.29	(0.59, 8.51)	2.87 (2.18)	0.11
Nepal	0.50	(0.12, 2.50)	0.70 (0.69)	0.81

Figure 2.96: Posterior densities for the treatment effect odds ratios, ACS-ITT.

175

Figure 2.97: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on day 28 shortness of breath for the primary model fit to the ACS-ITT set.

2.3.7 Modified Medical Research Council (mMRC) breathlessness scale at day 28

The mMRC scale was only asked of participants who responded "yes" to the question of new or worsening breathlessness since COVID. Therefore, the distribution of this outcome scale is conditional on the patient responding that they were experiencing new or worse breathlessness since having COVID. In the following tables "Not asked" refers to participants who responded "no" to the question of breathlessness.

Table 2.117: Summary of mMRC scale at day 28 by treatment group, anticoagulation domain, ACS-ITT.

Anticoagulation intervention	Patients	Known	With exercise	Up a slight hill	Slow for age	After 100 metres	Can't leav
Low-dose	610	577	40 (7%)	47 (8%)	12 (2%)	14 (2%)	
Intermediate-dose	613	584	50 (9%)	39 (7%)	11 (2%)	8 (1%)	
Low-dose with aspirin	283	271	26 (10%)	16 (6%)	15 (6%)	1 (0%)	
Therapeutic-dose	50	44	2 (5%)	4 (9%)	3 (7%)	2 (5%)	
Overall	**1556**	**1476**	**118 (8%)**	**106 (7%)**	**41 (3%)**	**25 (2%)**	

Table 2.118: Summary of mMRC scale at day 28 by treatment group, antiviral domain, AVS-ITT.

Antiviral intervention	Patients	Known	With exercise	Up a slight hill	Slow for age	After 100 metres	Can't leave hous
Standard of care	73	67	5 (7%)	15 (22%)	5 (7%)	9 (13%)	1 (1%)
Nafamostat	82	73	9 (12%)	12 (16%)	5 (7%)	8 (11%)	2 (3%)
Overall	**155**	**140**	**14 (10%)**	**27 (19%)**	**10 (7%)**	**17 (12%)**	**3 (2%)**

2.3.7.1 FAS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, region, site nested within region, and epoch.
- **Set**: FAS-ITT

Figure 2.98: Observed distribution of mMRC breathlessness scale (mMRCbs) at day 28 by treatment group, anticoagulation domain, FAS-ITT.

Table 2.119: Summary of model parameters (fixed-effects odds-ratios) for mMRC breathlessness scale at day 28 outcome model fit to the FAS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.68	(0.33, 1.39)	0.73 (0.27)	0.86
Intermediate-dose	0.74	(0.53, 1.03)	0.75 (0.13)	0.96
Low-dose with aspirin	1.11	(0.74, 1.68)	1.14 (0.24)	0.31
Therapeutic-dose	0.85	(0.35, 2.01)	0.93 (0.43)	0.65
Ineligible aspirin	1.44	(0.55, 3.51)	1.59 (0.78)	0.23
Age $\geq$ 60	1.98	(1.45, 2.70)	2.01 (0.32)	0.00
Female	1.03	(0.77, 1.37)	1.04 (0.15)	0.42
Oxygen requirement	1.17	(0.83, 1.63)	1.19 (0.21)	0.18
Australia/New Zealand	2.60	(0.68, 9.38)	3.23 (2.42)	0.08
Nepal	0.44	(0.10, 2.32)	0.63 (0.81)	0.85

178

Figure 2.99: Observed distribution of mMRC breathlessness scale (mMRCbs) at day 28 by treatment group, antiviral domain, FAS-ITT.


Figure 2.100: Posterior densities for the treatment effect odds ratios, FAS-ITT.

Figure 2.101: Posterior Summaries (point - median, block - 75% CrI, line - 95% CrI) of odds ratio for epoch and site effects on mMRC breathlessness scale at day 28 for the outcome model fit to the FAS-ITT set.

2.3.7.2 AVS-ITT

- **Model**: cumulative logistic (ordinal) regression assuming proportional odds
- **Terms**: anticoagulation intervention, antiviral intervention, aspirin eligibility, age group, sex, oxygen requirement, CRP tertile
- **Set**: AVS-ITT

Table 2.120: Summary of model parameters (fixed-effects odds-ratios) for mMRC breathlessness scale at day 28 outcome model fit to the AVS-ITT set.

Parameter	Median	95% CrI	Mean (SD)	Pr(OR < 1)
Nafamostat	0.79	(0.40, 1.58)	0.84 (0.30)	0.75
Intermediate-dose	0.91	(0.40, 2.07)	0.99 (0.44)	0.59
Low-dose with aspirin	0.57	(0.14, 2.12)	0.71 (0.54)	0.80
Therapeutic-dose	1.56	(0.55, 4.40)	1.79 (1.04)	0.20
Age ≥ 60	2.32	(1.14, 4.87)	2.50 (0.96)	0.01
Female	1.43	(0.72, 2.81)	1.51 (0.54)	0.15
Oxygen requirement	1.67	(0.79, 3.67)	1.81 (0.75)	0.10
CRP (2nd tertile)	0.77	(0.33, 1.77)	0.84 (0.38)	0.73
CRP (3rd tertile)	0.86	(0.37, 1.97)	0.94 (0.42)	0.64
CRP (unknown)	1.04	(0.33, 3.05)	1.21 (0.72)	0.47

Figure 2.102: Posterior densities for the treatment effect odds ratios, AVS-ITT.

2.3.8 Quality of life as measured by EQ-5D-5L questionnaire at day 28

The EQ-5D-5L responses are described.

Table 2.121: Prevelance of 10 most frequent, and worst, reported EQ-5D-5L profiles by treatment (day 28), AVS-ITT.

Health state	Frequency		Cumulative	
	n	%	n	%
No nafamostat				
11111	25	37.9	25	37.9
11121	2	3	27	40.9
11211	2	3	29	43.9
11221	2	3	31	47
21111	2	3	33	50
21121	2	3	35	53
21222	2	3	37	56.1
21321	2	3	39	59.1
31332	2	3	41	62.1
11112	1	1.5	42	63.6
...				
45514	1	1.5	66	100
Nafamostat				
11111	27	36.5	27	36.5
11112	4	5.4	31	41.9
11211	3	4.1	34	45.9
21221	3	4.1	37	50
11121	2	2.7	39	52.7
11114	1	1.4	40	54.1
11133	1	1.4	41	55.4
11212	1	1.4	42	56.8
11213	1	1.4	43	58.1
11231	1	1.4	44	59.5
...				
54554	1	1.4	74	100

Table 2.122: Distribution of responses on the EQ-5D-5L (day 28), AVS-ITT.

EQ-5D-5L	No namafostat	Namafostat	Overall
Mobility			
1	40 (43)	43 (41)	83 (42)
2	13 (14)	18 (17)	31 (16)
3	11 (12)	8 (8)	19 (10)
4	2 (2)	4 (4)	6 (3)
5	0 (0)	1 (1)	1 (1)
Any mobility problem	26 (28)	31 (30)	57 (29)
Self care			
1	58 (78)	61 (70)	119 (74)
2	6 (8)	5 (6)	11 (7)
3	0 (0)	5 (6)	5 (3)
4	0 (0)	3 (3)	3 (2)
5	2 (3)	0 (0)	2 (1)
Any self care problem	8 (11)	13 (15)	21 (13)
Usual activities			
1	34 (35)	40 (37)	74 (36)
2	15 (15)	19 (18)	34 (17)
3	15 (15)	8 (7)	23 (11)
4	1 (1)	5 (5)	6 (3)
5	1 (1)	2 (2)	3 (1)
Any usual activities problem	32 (33)	34 (31)	66 (32)
Pain/discomfort			
1	40 (43)	47 (47)	87 (45)
2	19 (21)	14 (14)	33 (17)
3	6 (7)	8 (8)	14 (7)
4	1 (1)	4 (4)	5 (3)
5	0 (0)	1 (1)	1 (1)
Any pain/discomfort problem	26 (28)	27 (27)	53 (27)
Anxiety/depression			
1	47 (55)	41 (39)	88 (46)
2	9 (11)	15 (14)	24 (13)
3	7 (8)	10 (10)	17 (9)
4	2 (2)	7 (7)	9 (5)
5	1 (1)	0 (0)	1 (1)
Any anxiety/depression problem	19 (22)	32 (30)	51 (27)

Table 2.123: Descriptive summary of EQ-5D VAS (day 28), AVS-ITT.

	No namafostat	Namafostat
n	73	82
Mean	78.8	78.5
SD	16.6	17.9
Median	85.0	82.5
Mode	90	90
Min	10	20
Max	100	100
Missing, n (%)	11 (15.07)	10 (12.2)

2.4 Domain Specific Outcomes

2.4.1 Antiviral Domain

The antiviral domain-specific outcomes were:

- viral clearance at days 3 and 7
- viral load at days 3 and 7
- safety:

    - elevation of Alanine Transaminase (ALT) or Aspartate Transaminase (AST)
    - elevated of serum potassium (> 5.5 mmol/L)
    - decrease of serum sodium (< 125 mmol/L)
    - major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH)
    - clinically relevant non-major bleeding (as defined by the ISTH)
    - thrombophlebitis/vasculitis at IV line site

The SAP specifies that descriptive summaries are to be reported for the antiviral specific outcomes.

2.4.1.1 Viral Clearance

The SAP specified that viral clearance was to be summarised at days 3 and 7. However, most participants did not have any PCR tests recorded during their hospital stay (Table 2.124), and those that did had inconsistent timing of the tests (Table 2.125).

Table 2.124: Descriptive summary of participant PCR testing.

Variable	Standard of care	Nafamostat
Assigned	73	82
Any tests	33	39
Proportion	0.45	0.48
Total tests	55	67
Mean number of tests	0.75	0.82
Max number of tests	5	8

Table 2.125: Descriptive summary of daily PCR testing, study days 1 to 7.

Day	Standard of care					Nafamostat				
	Patients	Tests	Positive	Negative	Indeterminate	Patients	Tests	Positive	Negative	Indeterminate
1	73	12 (16)	9 (75)	2 (17)	1 (8)	82	9 (11)	8 (89)	1 (11)	0 (0)
2	73	5 (7)	4 (80)	1 (20)	0 (0)	82	5 (6)	4 (80)	0 (0)	1 (20)
3	67	11 (16)	9 (82)	2 (18)	0 (0)	79	12 (15)	11 (92)	1 (8)	0 (0)
4	63	3 (5)	3 (100)	0 (0)	0 (0)	72	8 (11)	7 (88)	1 (12)	0 (0)
5	51	4 (8)	4 (100)	0 (0)	0 (0)	55	4 (7)	2 (50)	2 (50)	0 (0)
6	41	6 (15)	5 (83)	1 (17)	0 (0)	43	6 (14)	5 (83)	1 (17)	0 (0)
7	33	5 (15)	5 (100)	0 (0)	0 (0)	35	10 (29)	10 (100)	0 (0)	0 (0)

2.4.1.2 Viral Load

The SAP specified a descriptive summary of viral load to days 3 and 7, and change in viral load from baseline. Very few participants (24 of 156) had baseline cycle threshold values recorded so there was little data for looking at change in viral load from baseline. Additionally, most participants had no cycle threshold values reported their hospital stay.

Table 2.126: Descriptive summary of participant cycle threshold values.

Variable	Standard of care	Nafamostat
Assigned	73	82
Any Ct values	19 (26)	24 (29)
Total Ct values	27	43
Max number of Ct values	2	6

Table 2.127: Descriptive summary of daily Ct values, study days 1 to 7.

| Day	Standard of care					Nafamostat				
	Patients	Tests	Positive	Ct value	Median Ct value	Patients	Tests	Positive	Ct value	Median Ct value
1	73	12 (16)	9 (75)	6 (67)	26	82	9 (11)	8 (89)	5 (62)	25
2	73	5 (7)	4 (80)	2 (50)	28	82	5 (6)	4 (80)	3 (75)	29
3	67	11 (16)	9 (82)	5 (56)	32	79	12 (15)	11 (92)	9 (82)	22
4	63	3 (5)	3 (100)	3 (100)	28	72	8 (11)	7 (88)	6 (86)	24
5	51	4 (8)	4 (100)	4 (100)	26	55	4 (7)	2 (50)	2 (100)	20
6	41	6 (15)	5 (83)	3 (60)	28	43	6 (14)	5 (83)	4 (80)	22
7	33	5 (15)	5 (100)	3 (60)	26	35	10 (29)	10 (100)	7 (70)	29
8	27	2 (7)	1 (50)	0 (0)	NA	29	2 (7)	2 (100)	2 (100)	28

Figure 2.103: Cycle threshold values days 1 to 7. Line segments join values measured on the same individual.

2.4.1.3 Elevation of Alanine Transaminase (ALT) or Aspartate Transaminase (AST)

The SAP specified that elevation of Alanine Transaminase (ALT) or Aspartate Transaminase (AST) to more than 5 times the upper limit of normal will be summarised. The collected values were reported on IU/L, therefore a threshold of 150 IU/L was used rather than 5 times the upper limit of normal. The number of participants with any ALT/AST tests reported, and the number with values exceeding 150 IU/L are reported in Table 2.128.

Daily summaries are reported in Table 2.129 and Table 2.130.

Table 2.128: Descriptive summary of participant AST/ALT levels.

Variable	Standard of care	Nafamostat
Assigned	73	82
Any ALT tests, n (% of assigned)	63 (86)	71 (87)
Any ALT > 150, n (% of tested)	11 (17)	12 (17)
Any AST tests, n (% of assigned)	52 (71)	60 (73)
Any AST > 150, n (% of tested)	2 (4)	6 (10)
Total days	553	586
Total days ALT tested, n (% of days)	275 (50)	316 (54)
Total days ALT > 150, n (% of tests)	33 (12)	35 (11)
Total days AST tested, n (% of days)	185 (33)	254 (43)
Total days AST > 150, n (% of tests)	2 (1)	10 (4)

Table 2.129: Descriptive summary of daily ALT levels (IU/L) and testing.

Study Day	Standard of care				Nafamostat			
	Patients	Tested (% of patients)	Median	> 150 IU/L (% of tests)	Patients	Tested (% of patients)	Median	> 150 IU/L (% of tests)
1	73	43 (59)	40	1 (2)	82	51 (62)	38	1 (2)
2	73	36 (49)	52	2 (6)	82	46 (56)	50	3 (7)
3	67	32 (48)	42	3 (9)	79	42 (53)	50	5 (12)
4	63	29 (46)	57	6 (21)	72	34 (47)	53	4 (12)
5	51	18 (35)	64	3 (17)	55	26 (47)	66	5 (19)
6	41	18 (44)	56	4 (22)	43	22 (51)	52	4 (18)
7	33	17 (52)	81	4 (24)	35	20 (57)	64	6 (30)
8	27	12 (44)	83	3 (25)	29	18 (62)	60	4 (22)
9	17	8 (47)	38	3 (38)	21	6 (29)	36	1 (17)
10	13	6 (46)	36	2 (33)	15	4 (27)	44	0 (0)
11	11	5 (45)	46	1 (20)	11	6 (55)	31	0 (0)
12	9	3 (33)	23	1 (33)	8	6 (75)	40	0 (0)
13	7	4 (57)	30	0 (0)	6	3 (50)	59	0 (0)
14	6	3 (50)	31	0 (0)	5	3 (60)	32	0 (0)
15	5	3 (60)	19	0 (0)	5	2 (40)	25	0 (0)
16	5	3 (60)	45	0 (0)	4	3 (75)	28	0 (0)
17	5	4 (80)	36	0 (0)	4	1 (25)	26	0 (0)
18	5	3 (60)	56	0 (0)	4	2 (50)	36	0 (0)
19	5	4 (80)	40	0 (0)	4	3 (75)	22	0 (0)
20	5	3 (60)	39	0 (0)	4	2 (50)	34	0 (0)
21	4	4 (100)	50	0 (0)	3	2 (67)	40	0 (0)
22	4	4 (100)	68	0 (0)	3	3 (100)	17	0 (0)
23	4	3 (75)	31	0 (0)	2	2 (100)	62	0 (0)
24	4	4 (100)	49	0 (0)	2	2 (100)	88	1 (50)
25	4	1 (25)	43	0 (0)	2	2 (100)	88	0 (0)
26	4	2 (50)	88	0 (0)	2	2 (100)	83	0 (0)
27	4	2 (50)	68	0 (0)	2	1 (50)	160	1 (100)
28	4	1 (25)	39	0 (0)	2	2 (100)	90	0 (0)

Table 2.130: Descriptive summary of daily AST levels (IU/L) and testing.

Study Day	Standard of care				Nafamostat			
	Patients	Tested (% of patients)	Median	> 150 IU/L (% of tests)	Patients	Tested (% of patients)	Median	> 150 IU/L (% of tests)
1	73	35 (48)	42	1 (3)	82	43 (52)	48	2 (5)
2	73	28 (38)	50	1 (4)	82	36 (44)	46	2 (6)
3	67	21 (31)	56	0 (0)	79	35 (44)	41	2 (6)
4	63	22 (35)	50	0 (0)	72	27 (38)	38	1 (4)
5	51	11 (22)	37	0 (0)	55	22 (40)	37	1 (5)
6	41	15 (37)	38	0 (0)	43	17 (40)	37	2 (12)
7	33	12 (36)	38	0 (0)	35	16 (46)	39	0 (0)
8	27	8 (30)	32	0 (0)	29	14 (48)	33	0 (0)
9	17	4 (24)	25	0 (0)	21	5 (24)	25	0 (0)
10	13	3 (23)	23	0 (0)	15	2 (13)	28	0 (0)
11	11	3 (27)	29	0 (0)	11	4 (36)	35	0 (0)
12	9	1 (11)	25	0 (0)	8	5 (62)	48	0 (0)
13	7	2 (29)	25	0 (0)	6	2 (33)	56	0 (0)
14	6	1 (17)	26	0 (0)	5	1 (20)	66	0 (0)
15	5	1 (20)	22	0 (0)	5	1 (20)	51	0 (0)
16	5	1 (20)	20	0 (0)	4	2 (50)	47	0 (0)
17	5	1 (20)	16	0 (0)	4	1 (25)	51	0 (0)
18	5	1 (20)	15	0 (0)	4	2 (50)	38	0 (0)
19	5	2 (40)	18	0 (0)	4	2 (50)	34	0 (0)
20	5	1 (20)	19	0 (0)	4	2 (50)	32	0 (0)
21	4	2 (50)	22	0 (0)	3	2 (67)	38	0 (0)
22	4	2 (50)	22	0 (0)	3	2 (67)	44	0 (0)
23	4	2 (50)	23	0 (0)	2	2 (100)	42	0 (0)
24	4	2 (50)	34	0 (0)	2	2 (100)	60	0 (0)
25	4	1 (25)	44	0 (0)	2	2 (100)	58	0 (0)
26	4	1 (25)	80	0 (0)	2	2 (100)	48	0 (0)
27	4	1 (25)	42	0 (0)	2	1 (50)	78	0 (0)
28	4	1 (25)	56	0 (0)	2	2 (100)	50	0 (0)

Table 2.131: Descriptive summary of participants with AST or ALT exceeding threshold.

Variable	Standard of care	Nafamostat
Assigned	73	82
Any ALT or AST tests, n (% of assigned)	63 (86)	71 (87)
Any ALT > 150 or AST > 150, n (% of tested)	12 (19)	13 (18)
Total days	553	586
Total days ALT or AST tested, n (% of days)	275 (50)	316 (54)
Total days ALT > 150 or AST > 150, n (% of tests)	34 (12)	37 (12)

2.4.1.4 Serum Potassium

Eight participants had at least one day on which they were tested and had a serum potassium level greater than 5.5 mmol/L, 7 assigned to Nafamostat, and 1 assigned to standard of care (Table 2.132). Six of the participants only had the one day exceeding 5.5 mmol/L, two had 2 days, and one had 3 days. For participants assigned to Nafamostat, all days where serum potassium exceeded 5.5 mmmol/L occurred during the first 8 study days. For the participant assigned to standard of care, the elevated potassium occurred on day 10 (Table 2.133).

Of the seven participants assigned to Nafamostat, one had no reported SAE/SAR which was for hyperkalaemia. For the other six participants details are provided in Table 2.134, Table 2.145, and Table 2.146.

Table 2.132: Descriptive summary of participant serum potassium levels (mmol/L) and testing.

Variable	Standard of care	Nafamostat
Assigned	73	82
Any tests	67	78
Any > 5.5 mmol/L	1	7
Total days	553	586
Total tests	321	361
Total > 5.5 mmol/L	1	11

Table 2.133: Descriptive summary of daily serum potassium levels (mmol/L) and testing.

Study Day	Standard of care				Nafamostat			
	Patients	Tested (% of patients)	Mean	> 5.5 (% of tests)	Patients	Tested (% of patients)	Mean	> 5.5 (% of tests)
1	73	49 (67)	4.05	0 (0)	82	60 (73)	4.07	0 (0)
2	73	44 (60)	3.99	0 (0)	82	48 (59)	4.38	0 (0)
3	67	38 (57)	4.14	0 (0)	79	49 (62)	4.41	1 (2)
4	63	34 (54)	4.05	0 (0)	72	37 (51)	4.50	2 (5)
5	51	24 (47)	4.27	0 (0)	55	29 (53)	4.48	3 (10)
6	41	21 (51)	4.19	0 (0)	43	28 (65)	4.48	1 (4)
7	33	18 (55)	4.14	0 (0)	35	21 (60)	4.40	1 (5)
8	27	12 (44)	4.26	0 (0)	29	20 (69)	4.58	2 (10)
9	17	10 (59)	4.39	0 (0)	21	10 (48)	4.63	0 (0)
10	13	6 (46)	4.60	1 (17)	15	7 (47)	4.07	0 (0)
11	11	8 (73)	4.28	0 (0)	11	7 (64)	4.29	0 (0)
12	9	4 (44)	4.30	0 (0)	8	6 (75)	4.10	0 (0)
13	7	5 (71)	4.18	0 (0)	6	4 (67)	4.12	0 (0)
14	6	4 (67)	4.05	0 (0)	5	2 (40)	4.45	0 (0)
15	5	3 (60)	4.47	0 (0)	5	2 (40)	4.30	0 (0)
16	5	3 (60)	4.53	0 (0)	4	3 (75)	4.57	0 (0)
17	5	4 (80)	4.15	0 (0)	4	2 (50)	3.50	0 (0)
18	5	3 (60)	4.07	0 (0)	4	4 (100)	4.65	1 (25)
19	5	4 (80)	4.25	0 (0)	4	3 (75)	4.47	0 (0)
20	5	3 (60)	4.33	0 (0)	4	2 (50)	4.30	0 (0)
21	4	4 (100)	3.98	0 (0)	3	2 (67)	4.50	0 (0)
22	4	4 (100)	4.00	0 (0)	3	3 (100)	4.53	0 (0)
23	4	3 (75)	4.20	0 (0)	2	2 (100)	4.55	0 (0)
24	4	4 (100)	4.22	0 (0)	2	2 (100)	4.45	0 (0)
25	4	2 (50)	3.75	0 (0)	2	2 (100)	4.65	0 (0)
26	4	3 (75)	4.37	0 (0)	2	2 (100)	4.20	0 (0)
27	4	2 (50)	4.25	0 (0)	2	2 (100)	4.25	0 (0)
28	4	2 (50)	4.45	0 (0)	2	2 (100)	4.35	0 (0)

Table 2.134: Elevated serum potassium SAE notes.

ID	Antiviral	Values	Onset date	SAE Term	Type	Notes from Site
ALF00014	Nafamostat	5.7	NA			
CAM00002	Nafamostat	5.9	2021-09-20	Hyperkalaemia	SAE	The patient was randomised to nafamostat and standard dose thromboprophylaxis. On Day 5 the patient had hyperkalaemia so nafamostat treatment was ceased.A separate email was sent to clarify whether or not nafamostat should continue after this patient's potassium levels normalised. In this email, I think they may have incorrectly stated it was hypokalaemia not hyperkalaemia. Unable to modify outcome of SAE, as it is locked. I have checked the pathology values following the SAE, and Potassium was restored to within normal range the following day (21/9/21), following cessation of IMP. SAE paper CRF was marked as resolved/recovered. Measured again on 23/9/21 and was within normal range. Measured again on 24/9/21 at 5.5 (higher than normal), and participant was discharged home the following day (25/9/21). No further blood test values available.
CAM00012	Nafamostat	5.9	2021-12-30	Hyperkalaemia	SAE	Nafamostat course finished on 30/12. K+ levels were noted to be at 5.9 on 30/12 and again on 31/12. Repeat K+ test on 31/12 showed K+ level of 5.2. PI has reported the hyperkalaemia is likely secondary to nafamostat as no other clinical reason for hyperkalaemia. not reported as an SAE as did not require any interventions or prolonged hospitalisaition or complications and K+ levels returned naturally
MID00010	Standard of care	5.6	NA			
MMC00078	Nafamostat	6.2	2021-11-17	Hyperkalaemia	SAR	Patient had been experiencing elevated potassium levels- 6.2 mmol/L. Nafamostat ceased and patient successfully treated with resonium. A protocol breach was also submitted regarding this patient receiving the drug incorrectly (charted and administered 500mg per day from 12th to 15h Nov). The error was then discovered and the dose reduced to 375mg until the 17th November when the SAE occured and nafamostat was ceased.
MMC00079	Nafamostat	5.7, 6	2021-11-23	Hyperkalaemia	SAE	This patient was randomised to nafamostat and intermediate dose thromboprophylaxis. They experienced hyperkalaemia (6.0) on day 6 (23-Nov-2021) of their treatment. Their baseline potassium was 5.1. They have a number of comorbidities (obesity, diabetes, chronic kidney disease, Iatrogenic immunosuppression). They were treated with Sodium Polystyrene (15mg x2 daily) on 23-Nov-21 and have since recovered. Treatment continued however the patient only received 12 hours of the infusion on day 7 due to poor IV access.
RNS00002	Nafamostat	5.7, 6.1, 5.7	2021-08-05	Hyperkalaemia	SAE	Serum potassium levels were 6.1 mmol/L on the 05Aug2021 - Day 4 post randomisation 05 Aug 2021, K 6.1 – ECG was normal with normal P and T waves. Pt was given Resonium A 30g po 06 Aug 2021, K 5.7, given a further Resonium A 30g po 07 Aug 2021 K 4.8 The patient was on Nafamostat 350mg IV continuously from the 02Aug2021 to 09Aug2021 The pt was discharged on no medications.
SVH00002	Nafamostat	6.1, 5.9	2021-09-02	Hyperkalaemia	SAE	Clinical Synopsis / Significant Events 21/8/21 - PCR Covid +ive 25/8/21 - hospital admission 27/8/21 - ICU admission -> HFNP. 28/8/21 - . Ongoing HFNP requirement 30/8/21 - self-proning overnight 31/8/21 - Remains on HFNP, supine throughout day, self-proning encouraged overnight 2/9/21- Dex changed to Hydrocort as ? contributing to HypoNa/HyperK 3/9/21 -Urine culters UTI 1/9 E Coli and Pseudomonas aeruginosa, started Tazocin from Augmentin to cover Pseudomonas aeruginosa 6/9/21 - Remains on HFNP 50L 50% 8/9/21 - Ongoing slow wean of HFNP 9/9/21 - Transitioned to NP, cleared for ward Dose was finished prior to high K+

2.4.1.5 Serum Sodium

One participant had any days on which they were tested and had a serum sodium level less than 125 mmol/L. This participant had serum sodium less than 125 mmol/L on two consecutive days (study days 26 and 27). They were assigned to standard of care in the antiviral domain.

Most participants had at least one test during their hospital admission (Table 2.135). A summary of serum sodium testing by study day is presented in Table 2.136.

Table 2.135: Descriptive summary of participant serum sodium levels (mmol/L) and testing.

Variable	Standard of care	Nafamostat
Assigned	73	82
Any tests	67	78
Any < 125 mmol/L	1	0
Total days	553	586
Total tests	325	367
Total < 125 mmol/L	2	0

Table 2.136: Descriptive summary of daily serum sodium levels (mmol/L) and testing.

Study Day	Standard of care				Nafamostat			
	Patients	Tested (% of patients)	Mean	< 125 (% of tests)	Patients	Tested (% of patients)	Mean	< 125 (% of tests)
1	73	49 (67)	136.14	0 (0)	82	60 (73)	137.13	0 (0)
2	73	44 (60)	137.41	0 (0)	82	50 (61)	137.50	0 (0)
3	67	39 (58)	137.23	0 (0)	79	49 (62)	136.43	0 (0)
4	63	34 (54)	137.38	0 (0)	72	39 (54)	135.62	0 (0)
5	51	25 (49)	137.20	0 (0)	55	29 (53)	134.66	0 (0)
6	41	22 (54)	137.45	0 (0)	43	28 (65)	135.25	0 (0)
7	33	18 (55)	136.33	0 (0)	35	22 (63)	136.32	0 (0)
8	27	12 (44)	136.08	0 (0)	29	20 (69)	133.95	0 (0)
9	17	10 (59)	136.40	0 (0)	21	10 (48)	134.60	0 (0)
10	13	6 (46)	134.67	0 (0)	15	7 (47)	134.00	0 (0)
11	11	8 (73)	136.12	0 (0)	11	7 (64)	135.14	0 (0)
12	9	4 (44)	134.25	0 (0)	8	6 (75)	134.50	0 (0)
13	7	5 (71)	135.80	0 (0)	6	4 (67)	136.50	0 (0)
14	6	4 (67)	136.00	0 (0)	5	3 (60)	136.00	0 (0)
15	5	3 (60)	134.00	0 (0)	5	2 (40)	139.00	0 (0)
16	5	3 (60)	136.33	0 (0)	4	3 (75)	136.67	0 (0)
17	5	4 (80)	137.50	0 (0)	4	2 (50)	133.50	0 (0)
18	5	4 (80)	136.50	0 (0)	4	4 (100)	136.50	0 (0)
19	5	4 (80)	134.75	0 (0)	4	3 (75)	137.33	0 (0)
20	5	3 (60)	134.33	0 (0)	4	2 (50)	136.50	0 (0)
21	4	4 (100)	135.75	0 (0)	3	2 (67)	137.00	0 (0)
22	4	4 (100)	136.00	0 (0)	3	3 (100)	137.33	0 (0)
23	4	3 (75)	136.33	0 (0)	2	2 (100)	136.50	0 (0)
24	4	4 (100)	136.00	0 (0)	2	2 (100)	137.00	0 (0)
25	4	2 (50)	137.50	0 (0)	2	2 (100)	136.00	0 (0)
26	4	3 (75)	133.67	1 (33)	2	2 (100)	138.00	0 (0)
27	4	2 (50)	132.50	1 (50)	2	2 (100)	140.50	0 (0)
28	4	2 (50)	133.50	0 (0)	2	2 (100)	141.00	0 (0)

2.4.1.6 Bleeding Events

2.4.1.6.1 Major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH)

One participant randomised to the antiviral domain experienced a major bleeding event (Table 2.137). Two events were recorded for this participant on study days 5 and 6. This participant was also assigned to the *intermediate-dose* intervention in the anticoagulation domain.

An SAR was recorded for this event (onset date 2021-08-30), details are provided in Table 2.138 and Table 2.146.

Table 2.137: Descriptive summary of major bleeding (ISTH) events.

Variable	Standard of care	Nafamostat
Assigned	73	82
Total days in hospital	553	586
Any major bleeding (patient)	0	1
Total major bleeding (days)	0	2

Table 2.138: Major bleeding SAEs/SARs notes.

Patient ID	Date of SAE onset	Concurrant Disorder / Medication?	Notes from Site
WES00039	2021-08-30	Medication - Augmentin Duo Forte, Desvenlafaxine, dexamethosone, seretide, coloxyl with senna, meloxicam	Bleed was diagnosed on CT scan performed 30/8 at 13:49. The last dose of enoxaparin was given at 08:53 on 30/8. Nafamostat was ceased at 14:18 on 30/8. The Hb was 149 on 26/8 at 00:01 (prior to randomization on 26/8), 135 on 27/8 at 02:00, 125 on 29/8 at 04:07 and 123 on 30/9 at 09:28. The onset of abdominal pain was the morning of 30/8. The Nadir Hb was 106 on 31/8 at 00:09, and has risen to 118 on 31/8 at 07:40 post transfusion. 4 units of FFP and 2 units of PRBCs given in the early hours of 31/8. Additionally 20mg protamine given 30/8 at 20:16. antiXa levels: 0.3 U/ml on 30/8 at 16:46, 0.15 U/ml on 30/8 at 21:02 and 0.12 U/ml on 31/8 at 07:40 At 09:28 on 30/8, PT was 14s, APTT 40s, INR 1.2, PLT 193, Creatinine 63 umol/l, eGR>90 and urea 6.8 mmol/l.

2.4.1.6.2 Clinically relevant non-major bleeding (as defined by the ISTH)

Two participants randomised to the antiviral domain had clinically relevant non-major bleeding reported on their day 28 form (Table 2.139). One participant was assigned to Nafamostat and intermediate-dose anticoagulation. The other was assigned to standard of care in the antiviral domain and therapeutic-dose anticoagulation.

An SAR was recorded for two of these events, details are provided in Table 2.140 and Table 2.146.

Table 2.139: Descriptive summary of clinically relevant non-major bleeding (ISTH) events reported at day 28.

Variable	Standard of care	Nafamostat
Assigned	73	82
Missing	11	13
Any non-major bleeding	1	6

Table 2.140: Non-major bleeding SAEs/SARs notes.

Patient ID	Date of SAE onset	Concurrant Disorder / Medication?	Notes from Site
MID00009	2021-09-23	Disorder: Lymphangi-olieomyomatosis (LAM) Medication: allopurinol, ceftriaxone, dexamethasone, frusemide, metformin, novorapid, sirolimus, umeclidinium,	Patient was randomised to nafamostat and intermediate dose anticoagulation and they developed a minor bleed. The clinical team made the decision to reduce the heparin dose (60mg to 40mg), and there were no further issues after this. Even though it is was a minor bleed and the patient outcome not serious, it warranted a clinical response. It was felt that the bleeding was mild but persistent and increasing over a couple of days and was a potential warning sign of a life threatening event as she would not have tolerated a major pulmonary haemorrhage – she was for ward based ceiling of care despite young age because of her co-morbidities. Happily the bleeding resolved with a reduction in enoxaparin dose – I don't know whether it was going to resolve anyway.
RPH00005	2022-03-25	Medications: amoxi-cillin/clavulanate, fluticasone/salmeterol, morphine sulphate, pantoprazole, piperacillin/tazobactam	The patient was randomised, and began treatment, on the 16 March 2022. They were randomised to antiviral SoC, and therapeutic anticoagulation * The patient developed haemoptysis on 25 March 2022, which persisted up to 27 March 2022. * Anticoagulation treatment was ceased on the 25 March 2022. * The PI and respiratory team decided to stop anticoagulation treatment and have withdrawn the patient from the study, as they are scheduled for discharge

Table 2.141: Non-major bleeding details for non SAR/SAE events.

StudyPatientID	Antiviral	Anticoagulation	Notes from Site
ALF00014	Nafamostat	Intermediate-dose	Due to small volume haemoptysis, decision to withhold clexane and withdraw patient from anticoagulation domain; remained on nafamostat on 28/10/2021. Small volume haemopstysis continued to 30/10/2021, nafamostat ceased on 30/10/2021 (as possible anticoagulant properties)
ALF00015	Nafamostat	Intermediate-dose	Patient was elderly so had weak skin and was confused. Pulled IV out multiple times and had bleeding to hands/abdomen where IV and/or medication was given. NM bleeding recorded was due to this instance but was not considered serious.
MID00015	Nafamostat	Therapeutic-dose	On the day before discharge had several blood tinged sputum (every time they coughed) and it was discovered that the patient had rotten teeth and bleeding gums with a clot located in one of the teeth sockets. As a precaution clexane was reduced and no further bleeding was found. Patient was discharged next day with referral to dentist.
MID00019	Nafamostat	Therapeutic-dose	On the day of discharge had a nose bleed which took a while to stop. As a precaution the medical staff stopped clexane and Nafamostat with no further bleeding. Patient was then discharged later in the day.
WWB00004	Nafamostat	Therapeutic-dose	Patient had an episode of epistaxis on 15/11/21 (day 7 of trial) that lasted for 2-3 minutes then resolved with simple first aid measures. The dose of enoxaparin was withheld that evening then recommenced the following morning, and bloods the following morning (16/11) showed normal haemoglobin (145 g/L) and therapeutic anti-Xa level 4 hours post dose (0.71 U/ml). This event was considered non-serious.

2.4.1.6.3 Any Bleeding

For reference, all patients with any reported bleeding events are summarised in Table 2.142 and Table 2.143.

Table 2.142: Descriptive summary of bleeding events reported.

Variable	Standard of care	Nafamostat
Assigned	73	82
Major bleeding	0	1
Non-major bleeding	1	6
Any bleeding	1	7

Table 2.143: Line listing of patients who experienced bleeding events.

ID	Antiviral	Anticoagulation	Bleeding
ALF00014	Nafamostat	Intermediate-dose	Non-major
ALF00015	Nafamostat	Intermediate-dose	Non-major
MID00009	Nafamostat	Intermediate-dose	Non-major
MID00015	Nafamostat	Therapeutic-dose	Non-major
MID00019	Nafamostat	Therapeutic-dose	Non-major
RPH00005	Standard of care	Therapeutic-dose	Non-major
WES00039	Nafamostat	Intermediate-dose	Major
WWB00004	Nafamostat	Therapeutic-dose	Non-major

2.4.1.7 Thrombophlebitis/vasculitis at IV line site

Six participants assigned to Nafamostat had reported thrombophlebitis/vasculitis at IV line site (Table 2.144).

Table 2.144: Descriptive summary of thrombophlebitis/vasculitis at IV line site events.

Variable	Standard of care	Nafamostat
Assigned	73	82
Thrombophlebitis/vasculitis at IV line site (%)	0 (0)	6 (7)

2.5 Safety Listings

Listings of serious adverse events (SAEs) and serious adverse reactions (SARs) for participants randomised to the antiviral domain are included in Table 2.145 and Table 2.146.

2.5.1 SAEs

Table 2.145: SAE listing.

Patient ID	Onset date	SAE Term	Grade	Association with Study Drug	Protocol Treatment Start Date	Protocol Treatment End Date	Action Taken	Outcome	Resolution date
RNS00002	2021-08-05	Hyperkalaemia	1	Unlikely	2021-08-02	2021-08-04	None	Recovered/resolved	2021-08-06
SVH00002	2021-09-02	Hyperkalaemia	1	Possible	2022-08-26	2022-09-01	None	Recovered/Resolved	2022-09-03
CAM00002	2021-09-20	Hyperkalaemia	1	Possible	2021-09-16	2021-09-21	Intervention interupted	Recovered/Resolved	2021-09-21
ALF00013	2021-10-16	Nausea/Vomitting	NA	Possible	NA	NA	intervention withdrawn	NA	NA
CAM00008	2021-10-28	Hospital acquired pneumonia and empyema	3	Unlikely	2021-10-05	2021-10-12	None	Recovered/resolved	NA
ALF00014	2021-10-28	Small volume haemoptysis	NA	Possible	NA	NA	intervention withdrawn	NA	NA
MMC00079	2021-11-23	Hyperkalaemia	2	Probable	2021-11-15	2021-11-21	None	Recovered/resolved	2021-11-24
CAM00011	2021-11-28	elevated transaminases	2	Possible	2021-11-25	2021-11-28	intervention withdrawn	Recovered/Resolved	2021-11-30
CAM00012	2021-12-30	Hyperkalaemia	NA	Possible	2021-12-23	2021-12-30	None	Recovered/resolved	2021-12-31

2.5.2 SARs

Table 2.146: SAR listing.

Patient ID	Onset date	SAE Term	Grade	Association with Study Drug	SUSAR	Protocol Treatment Start Date	Protocol Treatment End Date	Action Taken	Outcome	Resolution date
WES00039	2021-08-30	Left retroperitoneal haemotoma	4	Probable	No	2021-08-26	2021-08-30	Intervention interupted	Recovered/resolved	2021-09-04
MID00009	2021-09-23	Haemoptysis	1	Possible	No	2021-09-20	2021-09-23	Dose reduced	Recovered/Resolved	2021-09-24
MMC00078	2021-11-17	Hyperkalaemia	3	Probable	No	2021-11-12	2021-11-17	intervention withdrawn	Recovered/resolved	2021-11-18
RPH00005	2022-03-25	Haemoptysis	2	Definite	No	2022-03-16	2022-03-25	intervention withdrawn	Recovered/resolved	2022-03-28

3 Appendix

3.1 Outcomes by Model Covariates (FAS-ITT)

3.1.1 Primary Outcome by Model Covariates (FAS-ITT)

Figure 3.1: Proportion of participants satisfying primary outcome criteria by age at randomisation, FAS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age.

Figure 3.2: Proportion of participants satisfying primary outcome criteria by sex, FAS-ITT.

Figure 3.3: Proportion of participants satisfying primary outcome criteria by supplemental oxygen requirement, FAS-ITT.

Figure 3.4: Proportion of participants satisfying primary outcome criteria by country of randomisation, FAS-ITT.

Figure 3.5: Proportion of participants satisfying primary outcome criteria by country and site of randomisation, FAS-ITT.

Figure 3.6: Proportion of participants satisfying primary outcome criteria by calendar time (month) of randomisation, FAS-ITT.

Figure 3.7: Proportion of participants satisfying primary outcome criteria by days since first symptoms at randomisation, FAS-ITT. Vertical dashed line indicates the pre-specified cut-point of 7 days.

3.1.2 Time to recovery to day 28 by model covariates (FAS-ITT)

Figure 3.8: Time to clinical recovery to day 28 by age group at randomisation, FAS-ITT.

Figure 3.9: Time to clinical recovery to day 28 by sex, FAS-ITT.

Figure 3.10: Time to clinical recovery to day 28 by supplemental oxygen requirement at randomisation, FAS-ITT.

Figure 3.11: Time to clinical recovery to day 28 by country of randomisation, FAS-ITT.

Figure 3.12: Time to clinical recovery to day 28 by country and site of randomisation, FAS-ITT.

Figure 3.13: Time to clinical recovery to day 28 by calendar time (month) of randomisation, FAS-ITT.

3.1.3 WHO outcome scale at day 28 by model covariates (FAS-ITT)

Figure 3.14: Distribution of WHO outcome scale day 28 by age at randomisation, FAS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age.

Figure 3.15: Distribution of WHO scale at day 28 by sex, FAS-ITT.

Figure 3.16: Distribution of WHO scale at day 28 by supplemental oxygen requirement at randomisation, FAS-ITT.

Figure 3.17: Distribution of WHO scale at day 28 by country of randomisation, FAS-ITT.

Figure 3.18: Distribution of WHO scale at day 28 by country and site of randomisation, FAS-ITT.

Figure 3.19: Distribution of WHO scale at day 28 by calendar time (month) of randomisation, FAS-ITT.

3.1.4 Mortality to day 28 by Model Covariates (FAS-ITT)

Figure 3.20: Proportion of participants who died by day 28 by age at randomisation, FAS-ITT. Vertical dashed line indicates the pre-specified cut-point of 60 years of age.

Figure 3.21: Proportion of participants who died by day 28 by sex, FAS-ITT.

Figure 3.22: Proportion of participants who died by day 28 by supplemental oxygen requirement at baseline, FAS-ITT.

Figure 3.23: Proportion of participants who died by day 28 by country of randomisation, FAS-ITT.

Figure 3.24: Proportion of participants who died by day 28 by country and site of randomisation, FAS-ITT.

Figure 3.25: Proportion of participants who died by day 28 by calendar time (month) of randomisation, FAS-ITT.

3.1.5 Days alive and free of hospital to day 28 by Model Covariates (FAS-ITT)

Figure 3.26: Distribution of days alive and free of hospital to day 28 by age groups, FAS-ITT.

Figure 3.27: Distribution of days alive and free of hospital to day 28 by sex, FAS-ITT.

Figure 3.28: Distribution of days alive and free of hospital to day 28 by supplemental oxygen requirement at baseline, FAS-ITT.

Figure 3.29: Distribution of days alive and free of hospital to day 28 by country of randomisation, FAS-ITT.

Figure 3.30: Distribution of days alive and free of hospital to day 28 by country and site of randomisation, FAS-ITT.

Figure 3.31: Distribution of days alive and free of hospital to day 28 by calendar time (month) of randomisation, FAS-ITT.

3.1.6 Days alive and free of ventilation to day 28 by Model Covariates (FAS-ITT)

Figure 3.32: Distribution of days alive and free of ventilation to day 28 by age groups, FAS-ITT.

Figure 3.33: Distribution of days alive and free of ventilation to day 28 by sex, FAS-ITT.

Figure 3.34: Distribution of days alive and free of ventilation to day 28 by supplemental oxygen requirement at randomisation, FAS-ITT.

Figure 3.35: Distribution of days alive and free of ventilation to day 28 by country of randomisation, FAS-ITT.

Figure 3.36: Distribution of days alive and free of ventilation to day 28 by country and site of randomisation, FAS-ITT.

Figure 3.37: Distribution of days alive and free of ventilation to day 28 by calendar time (month) of randomisation, FAS-ITT.

223

3.1.7 Presence of patient reported shortness of breath at day 28 by model covariates (FAS-ITT)

Figure 3.38: Proportion with patient reported shortness of breath at day 28 by age groups.

Figure 3.39: Proportion with patient reported shortness of breath at day 28 by sex.

Figure 3.40: Proportion with patient reported shortness of breath at day 28 by supplemental oxygen requirement at randomisation.

Figure 3.41: Proportion with patient reported shortness of breath at day 28 by country of randomisation.

Figure 3.42: Proportion with patient reported shortness of breath at day 28 by country and site of randomisation.

Figure 3.43: Proportion with patient reported shortness of breath at day 28 by calendar time (month) of randomisation.

3.1.8 Modified Medical Research Council (mMRC) breathlessness scale at day 28 (FAS-ITT)

Figure 3.44: Distrubtion of Modified Medical Research Council breathlessness scale (mMR-Cbs) at day 28 by age groups.

Figure 3.45: Distrubtion of Modified Medical Research Council breathlessness scale (mMR-Cbs) at day 28 by sex.

Figure 3.46: Distrubtion of Modified Medical Research Council breathlessness scale (mMR-Cbs) at day 28 by oxygen requirement.

Figure 3.47: Distrubtion of Modified Medical Research Council breathlessness scale (mMR-Cbs) at day 28 by country of randomisation.

Figure 3.48: Distrubtion of Modified Medical Research Council breathlessness scale (mMR-Cbs) at day 28 by country and site of randomisation.

Figure 3.49: Distrubtion of Modified Medical Research Council breathlessness scale (mMR-Cbs) at day 28 by calendar time (month) of randomisation.

## 3.2 Primary Model Posterior Predictive Summaries

3.2.1 Primary Outcome

Figure 3.50: Posterior predictive distribution for primary outcome by model covariates for primary model using FAS-ITT. Red diamond indicates observed proportions.

3.2.2 WHO outcome scale at day 28

Figure 3.51: Posterior predictive distribution for WHO scale by model covariates for primary model using ACS-ITT. Red diamond indicates observed proportions.

3.2.3 Mortality to day 28

Figure 3.52: Posterior predictive distribution for mortality to day 28 by model covariates for primary model using FAS-ITT. Red diamond indicates observed proportions.

3.2.4 Days alive and free of hospital to day 28

Figure 3.53: Posterior predictive distribution for days alive and free of hospital to day 28 by model covariates (intervention, country, and epoch) for primary model using FAS-ITT. Red diamond indicates observed proportions.

Figure 3.54: Posterior predictive distribution for days alive and free of hospital to day 28 by model covariates (site) for primary model using FAS-ITT. Red diamond indicates observed proportions.

### 3.2.5 Days alive and free of ventilation to day 28

Figure 3.55: Posterior predictive distribution for days alive and free of ventilation to day 28 by model covariates (intervention, country, and epoch) for primary model using FAS-ITT. Red diamond indicates observed proportions.

Figure 3.56: Posterior predictive distribution for days alive and free of ventilation to day 28 by model covariates (site) for primary model using FAS-ITT. Red diamond indicates observed proportions.

237

**3.2.6 Presence of patient reported shortness of breath at day 28**

Figure 3.57: Posterior predictive distribution for shortness of breath at day 28 by model covariates for primary model using FAS-ITT. Red diamond indicates observed proportions.

3.2.7 mMRC Breathlessness Scale

Figure 3.58: Posterior predictive distribution for mMRC scale by model covariates for primary model using FAS-ITT. Red diamond indicates observed proportions.